Argos Therapeutics (ARGS) 10-K 2 Apr 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Feb. 28, 2018	Jun. 30, 2017
Document Information [Line Items]
Entity Registrant Name	ARGOS THERAPEUTICS INC
Entity Central Index Key	1,105,533
Trading Symbol	args
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		7,909,765
Entity Public Float			$ 7.5
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 15,188,838	$ 52,973,376
Assets held for sale	600,000	1,452,172
Prepaid expenses	1,252,134	940,106
Other receivables	143,449	136,140
Total current assets	17,184,421	55,501,794
Property and equipment, net	3,582,323	40,951,577
Restricted cash		740,000
Other assets	11,020	11,020
Total assets	20,777,764	97,204,391
Current liabilities
Accounts payable	970,650	5,377,377
Accrued expenses	1,263,867	9,980,891
Current portion of notes payable	4,972,649	11,475,480
Current portion of other convertible notes	2,350,000
Current portion of manufacturing research and development obligation		3,653,203
Total current liabilities	9,557,166	30,609,838
Convertible note payable to related party	6,302,959
Long-term portion of other convertible notes	5,830,583
Long-term portion of notes payable		18,673,298
Long-term portion of manufacturing research and development obligation		4,509,033
Deferred liabilities	8,153,500	6,723,500
Warrants	167,636	20,926,061
Commitments
Stockholders’ equity (deficit)
Preferred stock $0.001 par value; 5,000,000 shares authorized as of December 31, 2016 and 2017; 0 shares issued and outstanding as of December 31, 2016 and 2017	0	0
Common stock $0.001 par value; 200,000,000 shares authorized as of December 31, 2016 and 2017; 2,063,158 and 5,906,620 shares issued and outstanding as of December 31, 2016 and 2017	5,907	2,063
Accumulated other comprehensive loss	(125,864)	(134,208)
Additional paid-in capital	363,450,204	338,288,657
Accumulated deficit	(372,564,327)	(331,986,817)
Total stockholders’ equity (deficit)	(9,234,080)	6,169,695
Total liabilities and stockholders’ equity (deficit)	20,777,764	97,204,391
Power Generation Agreements [Member]
Current liabilities
Current portion of lease obligations		122,887
Long-term portion of lease obligations		2,202,966
Lease Agreement [Member]
Current liabilities
Long-term portion of lease obligations		$ 7,390,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	5,906,620	2,063,158
Common stock, shares outstanding (in shares)	5,906,620	2,063,158

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue	$ 1,899,398	$ 945,468	$ 518,329
Operating expenses
Research and development	21,656,096	38,307,236	62,054,823
General and administrative	12,183,235	14,203,301	11,011,011
Impairment loss on property and equipment	27,254,385	741,114
Restructuring costs	6,031,779
Gain on disposal of impaired property	(2,767,540)
Total operating expenses	64,357,955	53,251,651	73,065,834
Operating loss	(62,458,557)	(52,306,183)	(72,547,505)
Other income (expense)
Interest income	64,485	57,326	25,382
Interest expense	(1,308,201)	(1,774,740)	(2,263,599)
Gain on early extinguishment of debt	2,356,478
Change in fair value of warrant liability	20,758,425	1,007,352
Other (loss) income	9,860	(11,865)	(2,799)
Other income (expense), net	21,881,047	(721,927)	(2,241,016)
Net loss	$ (40,577,510)	$ (53,028,110)	$ (74,788,521)
Net loss attributable to common stockholders per share, basic and diluted (in dollars per share)	$ (13.45)	$ (33.14)	$ (73.12)
Weighted average shares outstanding, basic and diluted (in shares)	3,017,409	1,600,286	1,022,862

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net loss	$ (40,577,510)	$ (53,028,110)	$ (74,788,521)
Other comprehensive loss:
Foreign currency translation (loss) gain	8,344	3,766	(25,061)
Unrealized (loss) gain on short-term investments		271	11,657
Total comprehensive loss	$ (40,569,166)	$ (53,024,073)	$ (74,801,925)

Consolidated Statements of Chan

Consolidated Statements of Changes In Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2014	982,870
Balance at Dec. 31, 2014	$ 983	$ 235,645,848	$ (124,841)	$ (204,170,186)	$ 31,351,804
Issuance of common stock (in shares)	95,309
Issuance of common stock	$ 95	10,681,337			10,681,432
Exercise of common stock options (in shares)	2,227
Exercise of common stock options	$ 2	201,086			201,088
Share-based compensation		4,014,938			4,014,938
Issuance of common stock under Employee Stock Purchase Plan (ESPP) (in shares)	1,669
Issuance of common stock under Employee Stock Purchase Plan (ESPP)	$ 2	207,214			207,216
Issuance of warrants		144,012			144,012
Cumulative translation adjustment			(25,061)		(25,061)
Unrealized gain on short-term investments			11,657		11,657
Net loss				(74,788,521)	(74,788,521)
Balance (in shares) at Dec. 31, 2015	1,082,075
Balance at Dec. 31, 2015	$ 1,082	250,894,435	(138,245)	(278,958,707)	(28,201,435)
Exercise of common stock options (in shares)	1,059
Exercise of common stock options	$ 1	133,569			133,570
Share-based compensation		4,933,988			4,933,988
Issuance of common stock under Employee Stock Purchase Plan (ESPP) (in shares)	3,322
Issuance of common stock under Employee Stock Purchase Plan (ESPP)	$ 3	262,816			262,819
Cumulative translation adjustment			3,766		3,766
Unrealized gain on short-term investments			271		271
Net loss				(53,028,110)	(53,028,110)
Issuance of common stock and warrants (in shares)	954,735
Issuance of common stock and warrants	$ 955	83,278,718			83,279,673
Issuance of restricted common stock to employees (in shares)	16,556
Issuance of restricted common stock to employees	$ 16	836,618			836,634
Issuance of fully vested common stock to directors (in shares)	2,608
Issuance of fully vested common stock to directors	$ 3	288,998			289,001
Common stock issuance costs		(2,640,414)			(2,640,414)
Exercise of warrants (in shares)	2,803
Exercise of warrants	$ 3	299,929			$ 299,932
Balance (in shares) at Dec. 31, 2016	2,063,158				2,063,158
Balance at Dec. 31, 2016	$ 2,063	338,288,657	(134,208)	(331,986,817)	$ 6,169,695
Issuance of common stock (in shares)	3,373,967
Issuance of common stock	$ 3,374	15,461,009			$ 15,464,383
Exercise of common stock options (in shares)
Share-based compensation		7,340,820			$ 7,340,820
Issuance of common stock under Employee Stock Purchase Plan (ESPP) (in shares)	1,428
Issuance of common stock under Employee Stock Purchase Plan (ESPP)	$ 1	11,755			11,756
Cumulative translation adjustment			8,344		8,344
Unrealized gain on short-term investments
Net loss				(40,577,510)	(40,577,510)
Issuance of restricted common stock to employees (in shares)	376,424
Issuance of restricted common stock to employees	$ 377	1,920,955			1,921,332
Issuance of warrants as payment of debt		87,100			87,100
Issuance of common stock as payment of debt (in shares)	91,643
Issuance of common stock as payment of debt	$ 92	339,908			$ 340,000
Balance (in shares) at Dec. 31, 2017	5,906,620				5,906,620
Balance at Dec. 31, 2017	$ 5,907	$ 363,450,204	$ (125,864)	$ (372,564,327)	$ (9,234,080)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net loss	$ (40,577,510)	$ (53,028,110)	$ (74,788,521)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	967,891	952,341	680,444
Share-based compensation expense	8,867,616	5,103,494	4,014,938
Common stock issued as payment for services		290,998
Amortization of debt issuance costs		34,004	216,424
Amortization of debt discount		140,816	116,042
Interest accrued on long-term debt	664,321		25,732
Impairment loss on property and equipment	27,254,385	741,114
Gain on early extinguishment of debt	(2,356,478)
Decrease in fair value of warrant liability	(20,758,425)	(1,007,352)
Gain on disposal of impaired property	(2,767,540)
Other		11,865	2,799
Changes in operating assets and liabilities:
Prepaid expenses and other receivables	(385,232)	(262,255)	153,449
Accounts payable	(2,222,657)	1,193,590	(136,981)
Accrued expenses	(3,591,577)	4,905,230	796,684
Manufacturing research and development obligation	(409,680)	384,800	4,301,884
Deferred liabilities	(110,000)	(137,500)	1,485,000
Net cash used in operating activities	(35,424,886)	(40,676,965)	(61,020,674)
Cash flows from investing activities
Purchase of property and equipment	(3,674,358)	(15,329,980)	(9,686,643)
Proceeds from sale of property and equipment	3,250,631
Purchases of short-term investments			(2,677,155)
(Payment to) receipt from restricted cash account securing letter of credit	740,000		585,000
Proceeds from maturity of short-term investments		1,003,431	20,702,000
Net cash provided by (used in) investing activities	316,273	(14,326,549)	8,923,202
Cash flows from financing activities
Proceeds from sale of common stock and warrants	15,464,383	105,213,087	8,570,000
Stock issuance costs		(2,374,072)
Proceeds from issuance of notes payable with detachable common stock warrants			12,500,000
Proceeds from issuance of convertible note payable to related party	6,000,000
Payments on notes payable	(24,113,786)	(1,562,500)	(35,480)
Proceeds from exercise of common stock warrants		299,932
Proceeds from exercise of employee stock purchase plan rights	11,756	262,819	207,233
Proceeds from exercise of common stock options		133,571	201,067
Net cash provided by (used in) financing activities	(2,684,153)	101,810,026	21,061,787
Effect of exchange rates changes on cash	8,228	3,720	(24,761)
Net (decrease) increase in cash and cash equivalents	(37,784,538)	46,810,232	(31,060,446)
Cash and cash equivalents
Beginning of period	52,973,376	6,163,144	37,223,590
End of period	15,188,838	52,973,376	6,163,144
Supplemental disclosure of cash flow information
Cash paid for interest	766,776	2,440,846	1,648,707
Supplemental disclosure of noncash investing and financing activities
Issuance of common stock for research and development and other services		290,998	2,111,432
Issuance of warrants in exchange for early extinguishment of debt	87,100
Issuance of convertible notes in exchange for early extinguishment of debt	8,650,584
Issuance of common stock in exchange for early extinguishment of debt	340,000
Interest capitalized on construction-in-progress		785,699	880,334
Purchases of property and equipment included in accounts payable and accrued expenses	2,470,118	3,073,708	2,658,958
Stock issuance costs included in accounts payable and accrued expenses		266,348
Lease Agreement [Member]
Cash flows from financing activities
Payment on lease obligations		(100,000)	(381,033)
Supplemental disclosure of noncash investing and financing activities
Lease obligations incurred		240,373	4,250,437
Power Generation Agreements [Member]
Cash flows from financing activities
Payment on lease obligations	(46,506)	(62,811)
Supplemental disclosure of noncash investing and financing activities
Lease obligations incurred		2,372,880
Issuance of Common Stock as Payment for Research and Development Services [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock issued as payment for services			$ 2,111,432

Note 1 - Organization and Accou

Note 1 - Organization and Accounting Policies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Argos Therapeutics, Inc. (the “Company”), was incorporated in the State of Delaware on May 8, 1997. The Company’s most advanced product candidate is rocapuldencel-T, which it is developing for the treatment of metastatic renal cell carcinoma (“mRCC”) and other cancers. The Company is currently conducting a pivotal Phase 3 February 2017, second 2018. 2 not The Company is developing AGS- 004, second 1 2 2b 004 004 2 004 004 Basis of Presentation and Going Concern The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has evaluated principal conditions and events that may one December 31, 2017, $372.6 December 31, 2017, $17.2 $9.6 $15.2 December 31, 2017 not may On March 3, 2017, March 6, 2017, $23.1 five 5,000 $26.00 $23.1 $23.1 In March 2017, $1.2 December 31, 2017. $3.2 December 31, 2017. In June 2017, $6.0 $6.0 In August 2017, $1.5 $0.85 third 2017 April 2018. In September 2017, $0.5 57,142 $5.2 $8.3 In November 2017, $0.5 34,499 $2.4 December 31, 2019. From June 2017 December 31, 2017, $15.5 March 16, 2018, $7.3 December 31, 2017. As of December 31, 2017, $15.2 $7.6 not 2018. may one one no may Until such time, if ever, as the Company can generate substantial product revenues, it expects to seek to raise additional funds through a combination of equity offerings, debt financings, government contracts, government and other third third no The consolidated financial statements include the accounts of the Company and DC Bio Corp., the Company’s Canadian wholly-owned subsidiary, an unlimited liability corporation incorporated in the Province of Nova Scotia. Significant intercompany transactions and accounts have been eliminated. On January 18, 2018, one twenty Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Principles of Consolidation The consolidated financial statements include the accounts of the Company and DC Bio Corp., the Company’s Canadian wholly-owned subsidiary, an unlimited liability corporation incorporated in the Province of Nova Scotia and Argos Therapeutics (Europe)S.à.r.l., the Company’s wholly-owned subsidiary, a société anonyme à responsabilité limitée incorporated in Luxembourg. Significant intercompany transactions and accounts have been eliminated. Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three December 31, 2016 2017, $52,723,376 $14,688,838, Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and short-term investments. Property and Equipment Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Property and equipment held under capital leases and leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to income. Repairs and maintenance costs are expensed as incurred. Impairment of Long-Lived Assets The Company evaluates its long-lived assets whenever significant events or changes in circumstances occur that indicate that the carrying amount of an asset may not $0.7 $27.3 December 31, 2016 2017, 3 No December 31, 2015. Accounting for Outstanding Warrants as Liabilities The Company has outstanding warrants issued in August 2016 December 31, 2017 The fair value of warrants recorded as liabilities is measured using the Black-Scholes valuation model. Inherent in the Black-Scholes valuation model are assumptions related to expected stock price volatility, expected life, risk-free interest rate and dividend yield. The risk-free interest rate is based on the U.S. Treasury five zero Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, 605. The Company has entered into license agreements with collaborators. The terms of these agreements have included nonrefundable signing and licensing fees, as well as milestone payments and royalties on any future product sales developed by the collaborators under these licenses. The Company assesses these multiple elements in accordance with ASC 605, These collaboration agreements are accounted for in accordance with Accounting Standards Update (“ASU”) No. 2009 13, 605 2009 13. third not Whenever the Company determines that an arrangement should be accounted for as a single unit of accounting, the Company must determine the period over which the performance obligations will be performed and revenue will be recognized, to the extent this is determinable. If the Company cannot reasonably estimate, to the extent this is determinable, the timing and the level of effort to complete its performance obligations under the arrangement, then the Company recognizes revenue under the arrangement on a straight-line basis over the period that the Company expects to complete such performance obligations. The Company’s license agreements with Pharmstandard International S.A. (“Pharmstandard”), Green Cross Corp. (“Green Cross”), Medinet Co., Ltd. (“Medinet”), and Lummy (Hong Kong) Co. Ltd. (“Lummy HK”) provide for, and any future license agreements it may may not no The Company’s current license agreements with Pharmstandard, Green Cross, Medinet and Lummy HK provide for, and any future license agreements the Company may may not not no The Company records deferred revenue when payments are received in advance of the culmination of the earnings process. This revenue is recognized in future periods when the applicable revenue recognition criteria have been met. In September 2006, 004. $39.8 $38.4 $1.4 September 2010, September 2010. May 2013. $5.4 May 2013 September 2015. $0.5 September 18, 2014 2 004 June 29, 2016, July 31, 2018. not The Company recognizes revenue from reimbursements earned in connection with the NIH and NIAID contract as reimbursable costs are incurred. The Company recognizes revenues from the achievement of milestones under the NIH and NIAID contract upon the accomplishment of any such milestone. For the years ended December 31, 2015, 2016 2017, $448,273, $807,968 $177,926, $38.3 December 31, 2017 December 31, 2017, $1.5 December 31, 2016 2017, $136,140 $31,977, no Income Taxes The Company provides for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not not Segment and Geographic Information Operating segments are defined as components of an enterprise engaging in business activities from which it may one Research and Development Research and development costs include all direct costs related to the development of the Company’s technology, including salaries and related benefits of research and development (“R&D”) personnel, depreciation of laboratory equipment, fees paid to consultants and contract research organizations, share-based compensation for R&D personnel, sponsored research payments and license fees. R&D costs are expensed as incurred. Share-Based Compensation The Company estimates the grant date fair value of its share-based awards and amortizes this fair value to compensation expense over the requisite service period or vesting term (see Note 11 Comprehensive Income (Loss) ASC 220, Comprehensive Income, Foreign Currency Translation Gains and losses from foreign currency transactions are reflected in income currently. The Company has identified the functional currency of its subsidiaries with foreign operations as the applicable local currency. The translation from the applicable local currency to United States dollars is performed using the exchange rate in effect as of the balance sheet date. Revenue and expense accounts are translated using the average exchange rate experienced during the period. Adjustments resulting from the translation of the Company’s subsidiaries’ financial statements from its functional currency to the United States dollar are not Interest Expense During the years ended December 31, 2015, 2016 2017, $23.1 March 2017, November 2017 ( 6 8 Recently Issued Accounting Pronouncements Not In May 2014, 2014 09 , Revenue from Contracts with Customers (“ASU 2014 09” 2014 09 not December 15, 2016. August 2015, 2015 14, Revenue from Contracts with Customers: Deferral of the Effective Date, 2014 09 one December 15, 2017, not first 2018. 2016 10, Identifying Performance Obligations and Licensing, two 2014 09 The Company plans to adopt the full retrospective method effective January 1, 2018, third no first 2018 In August 2016, ASU 2016 15, Statement of Cash Flows (Topic 230 entation of certain items in the statement of cash flows including but not December 15, 2017, January 1, 2018. In February 2016, 2016 02, Leases (Topic 842 2016 02" 2016 02 not 12 12 842 840 Leases December 15, 2018, January 1, 2019. In November 2016, 2016 18, Restricted Cash 2016 18" 2016 18 2016 18 first 2019, 2016 18 not Recently Adopted Accounting Standards In August 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09” 2016 09 December 31, 2017 no

Note 2 - Fair Value of Financia

Note 2 - Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. The estimated fair values of all of the Company’s financial instruments, excluding long-term debt, approximate their carrying amounts in the consolidated balance sheets as of December 31, 2016 December 31, 2017. As of December 31, 2016 December 31, 2017, December 31, 2016 December 31, 2017, three one three 1, 2, 1, 3, The Company’s Level 1 1 no 2 may The Company’s warrant liability is classified as a Level 3 10 During the years ended December 31, 2016 2017, no 1, 2, 3 As of December 31, 2016 2017, Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 45,389,314 $ — $ — $ 45,389,314 Restricted cash – long-term 740,000 — — 740,000 Total assets at fair value $ 46,129,314 $ — $ — $ 46,129,314 Liabilities Warrants $ — $ — $ 20,926,061 $ 20,926,061 Total liabilities at fair value $ — $ — $ 20,926,061 $ 20,926,061 Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 4,098,037 $ — $ — $ 4,098,037 Total assets at fair value $ 4,098,037 $ — $ — $ 4,098,037 Liabilities Warrants $ — $ — $ 167,636 $ 167,636 Total liabilities at fair value $ — $ — $ 167,636 $ 167,636 Changes in the fair value of the Company’s Level 3 December 31, 2016 2017 10 Balance as of December 31, 2015 $ — Issuance of warrants at fair value 21,933,413 Unrealized gain during the year (1,007,352 ) Balance as of December 31, 2016 $ 20,926,061 Unrealized gain during the year (20,758,425 ) Balance as of December 31, 2017 $ 167,636 The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and estimated fair value of money-market funds included in cash and cash equivalents and restricted cash as of December 31, 2016 December 31, 2017 As of December 31, 2016 Amortized Cost Gross Gross Aggregate Money-market funds $ 45,389,314 $ — $ — $ 45,389,314 Restricted cash – long-term 740,000 — — 740,000 $ 46,129,314 $ — $ — $ 46,129,314 As of December 31, 2017 Amortized Cost Gross Gross Aggregate Money-market funds $ 4,098,037 $ — $ — $ 4,098,037 $ 4,098,037 $ — $ — $ 4,098,037 The fair value of the Company’s debt was derived by evaluating the nature and terms of each note, considering the prevailing economic and market conditions as of each balance sheet date and based on the Level 2 December 31, 2016 $29.8 $30.1 December 31, 2017 $19.1 $19.5 6

Note 3 - Restructuring Activiti

Note 3 - Restructuring Activities and Related Impairments of Property and Equipment and Leases	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	3. As discussed in Note 1, 3 February 2017, 290 4 8, $6.0 $27.3 December 31, 2017. Workforce Action Plan On March 10, 2017, 46 38% 122 76 March 2017. 39 December 31, 2017. $1.2 December 31, 2017, December 31, 2017. $3.2 December 31, 2017. CTI Lease Agreement In January 2017, ten two five 40,000 $2.4 first 2018. February 2017 On March 17, 2017 not not 12% March 31, 2017, March 17, 2017. $2.4 $0.7 March 2017 $1.7 April 2017 $0.1 December 31, 2017, $1.6 $0.9 December 31, 2017. Impairment of Centerpoint Facility and Construction-in-Progress During the three March 2017, no $0.7 December 31, 2017. December 31, 2017, $18.3 November 2017, third $1.8 $1.8 December 31, 2017. The restructuring liability during the year ended December 31, 2017 Severance and Lease and Other Total Balance as of December 31, 2016 $ — $ — $ — Restructuring costs 4,416,189 1,615,590 6,031,779 Acceleration of stock options and restricted stock (3,171,751 ) — (3,171,751 ) Cash payments (1,244,438 ) (1,615,590 ) (2,860,028 ) Balance as of December 31, 2017 $ — $ — $ —

Note 4 - Property and Equipment

Note 4 - Property and Equipment	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and equipment consisted of the following as of December 31, 2016 2017: Useful Life 2016 2017 Office furniture and equipment 7 $ 657,875 $ 639,603 Computer equipment 3 1,018,173 989,137 Computer software 3 3,146,978 3,146,978 Laboratory equipment 7 5,709,215 6,050,640 Leasehold improvements 5 2,435,530 2,435,530 Assets related to facility lease obligation 8,070,033 — Construction-in-progress 28,807,957 — Total property and equipment, net 49,845,761 13,261,888 Less: Accumulated depreciation and amortization (8,894,184 ) (9,679,565 ) Property and equipment, net $ 40,951,577 $ 3,582,323 The Company reviews its property and equipment for impairment whenever events or changes indicate its carrying value may not 3, three March 31, 2017 no $0.7 December 31, 2017 $1.1 December 31, 2017. $6.1 December 31, 2017 no During the year ended December 31, 2016, fourth 2016 not three March 2017, three third three $1,452,172 December 31, 2016 $741,114 December 31, 2016. Centerpoint Facility and Construction-in-Progress As of December 31, 2016, 8 3, no $18.3 December 31, 2017. In November 2017, third $1.8 $1.8 December 31, 2017. Construction-in-progress under capital leases included $2.4 $0 December 31, 2016 December 31, 2017, December 31, 2016 December 31, 2017, $2.7 $0, Depreciation and amortization expense was as follows: Year ended December 31, 2015 $ 680,444 Year ended December 31, 2016 $ 952,341 Year ended December 31, 2017 $ 967,891

Note 5 - Income Taxes

Note 5 - Income Taxes	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	5. No 1997. Significant components of the Company’s deferred tax assets and liabilities consisted of the following: December 31, 2016 2017 U.S. federal and state net operating loss carryforwards $ 89,445,428 $ 69,850,442 Foreign net operating loss carryforwards 1,526,207 1,649,765 Contribution carryforwards 4,245 2,202 Research and development credits 7,705,933 8,477,318 Investment tax credits 30,363 32,473 Share-based compensation 1,586,780 2,725,223 Other accruals 917,376 84,357 Deferred revenue 1,120,772 1,044,788 Property and equipment 257,192 27,628 Total deferred tax assets 102,594,296 83,894,196 Valuation allowance for deferred assets (102,594,296 ) (83,894,196 ) Net deferred tax assets $ — $ — As of December 31, 2016 2017, not not December 31, 2017 $18,700,100, As of December 31, 2017, $300.8 $338.5 $6.1 $6.1 2018, 2017, 2026 2026, December 31, 2017, $0.2 December 31, 2017, $8.2 $0.3 2020 2024, December 31, 2017, $32,500 2024. The utilization of the NOL and tax credit carryforwards may 382 1986, may 50 three 382 382 2014 382. 382 $28,156,600 not As of December 31, 2017, no Taxes computed at the statutory U.S. federal income tax rate of 34.0% December 31, 2015, 2016 2017 2015 2016 2017 Amount Percent of Pretax Earnings Amount Percent of Pretax Earnings Amount Percent of Pretax Earnings U.S. federal tax statutory rate $ (25,428,097 ) 34.0 % $ (18,029,558 ) 34.0 % $ (13,796,353 ) 34.0 % State taxes (net of federal benefit) (1,936,719 ) 2.6 % (1,034,566 ) 2.0 % (801,406 ) 2.0 % U.S. federal research and development tax credits (2,135,940 ) 2.9 % (1,368,171 ) 2.6 % (1,038,768 ) 2.6 % Other nondeductible expenses 1,032,480 (1.4 %) 760,287 (1.5 %) 1,973,462 (4.9 %) Increase in unrecognized tax benefits 640,782 (0.9 %) 410,451 (0.8 %) 311,630 (0.8 %) Change in effective state tax rate 1,190,519 (1.6 %) 1,655,991 (3.1 %) 12,871 (0.0 %) Expiration of NOL & contribution carryforwards 9,590,101 (12.8 %) — (0.0 %) 136,325 (0.3 %) Adjustment for change in federal effective tax rate — (0.0 %) — (0.0 %) 41,255,460 (101.7 %) Change in fair value of warrant liability — (0.0 %) — (0.0 %) (7,467,843 ) 18.4 % Change in valuation allowance 16,705,784 (22.3 %) 17,691,710 (33.4 %) (18,700,100 ) 46.1 % Deferred tax asset true-ups 341,090 (0.5 %) (86,144 ) 0.2 % (1,885,278 ) 4.6 % Provision for income taxes $ — 0.0 % $ — 0.0 % $ — 0.0 % On September 18, 2015, 97, 5% 4% 2016. 2015 $1,190,500. August 4, 2016, 4% 3% 97. 2016 $1,656,000. June 28, 2017, 3% 2.5% 97. 2017 $16,810. On December 22, 2017, 21% December 31, 2017. December 31, 2017 21% $41.3 The Tax Legislation also implements a territorial tax system. Under the territorial tax system, in general, the Company's foreign earnings will no not no The SEC staff issued Staff Accounting Bulletin 118, 118, 118 As of December 31, 2017, $41.3 December 31, 2017 not 2018. The Company also considers it likely that further technical guidance regarding certain aspects of the new provisions included in the Tax Reform Act, as well as clarity regarding state income tax conformity to current federal tax code, may December 31, 2017 not The Company will continue to assess the impact of the recently enacted tax law on its business and consolidated financial statements. The Company had gross unrecognized tax benefits of $3,206,300 January 1, 2017. December 31, 2017, $3,517,900 none not 12 The Company’s policy is to recognize interest and penalties related to uncertain tax positions in the provision for income taxes. As of December 31, 2016 2017, no The Company has analyzed its filing positions in all significant federal and state jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, the Company is no 2014 2014 may No The following is a tabular reconciliation of the Company’s change in gross unrecognized tax positions during the years ended December 31, 2015, 2016 2017: 2015 2016 2017 Beginning balance $ 2,155,000 $ 2,795,800 $ 3,206,300 Gross increase for tax positions related to current periods 640,800 410,500 311,600 Gross (decrease) increase for tax positions related to prior periods — — — Ending balance $ 2,795,800 $ 3,206,300 $ 3,517,900

Note 6 - Notes Payable and Conv

Note 6 - Notes Payable and Convertible Notes Payable	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Notes payable and convertible notes payable consisted of the following as of December 31, 2016 2017: December 31, December 31, Notes payable under the venture loan and security agreement, including accrued interest 24,035,029 $ — Less debt discount and debt issuance costs (320,409 ) — Notes payable under the venture loan and security agreement, net 23,714,620 — Convertible note payable to Pharmstandard, including accrued interest — 6,302,959 Convertible note payable to Invetech, including accrued interest — 5,845,655 Convertible note payable to Saint-Gobain, including accrued interest — 2,334,929 Note payable to Medinet, including accrued interest 6,403,186 4,958,824 Other notes payable 30,972 13,825 Total debt 30,148,778 19,456,192 Less current portion of convertible note payable to Invetech, including accrued interest — (1,300,000 ) Less current portion of convertible note payable to Saint-Gobain, including accrued interest — (1,050,000 ) Less current portion of note payable to Medinet, including accrued interest — (4,958,824 ) Less current portion of other notes payable (11,475,480 (13,825 ) Long-term portion of notes payable and convertible notes payable $ 18,673,298 12,133,543 Convertible Note Payable to Invetech. 7, $8.3 $5.2 $2.3 $0.7 On September 22, 2017, $0.5 57,142 $0.2 $5.2 $8.3 $1.5 December 31, 2017. The original principal amount of the Invetech Note is $5.2 September 30, 2020. 6.0% not The Company is required to make quarterly installment payments under the Invetech Note for the fiscal quarters ending December 31, 2017 March 31, 2018, $0.4 $0.2 $0.2 June 30, 2018 March 31, 2019, $0.3 $150,000 $150,000 June 30, 2019 June 30, 2020, $150,000, December 31, 2017, $0.2 The Invetech Note also provides that on the anniversary of the issue date of the Invetech Note for each of the first three $250,000, no As detailed further below, Invetech may $10.00 • Maturity of the Invetech Note 75 may, not • Change of Control may, not • Default may, not Subject to the aforementioned conversion rights of Invetech, the Company may Convertible Note Payable to Saint-Gobain. November 22, 2017, $0.5 34,499 $2.4 December 31, 2019. The original principal amount of the Note is $2,360,000. September 30, 2020. 6.0% not The Company is required to make quarterly installment payments under the Saint-Gobain Note for the fiscal quarters ending December 31, 2017 March 31, 2018, $340,000, $200,000 $140,000 June 30, 2018 September 30, 2018, $245,000, $125,000 $120,000 December 31, 2018 March 31, 2019, $220,000, $100,000 $120,000 December 31, 2017, March 31, 2018, June 30, 2018, September 30, 2018, December 31, 2018 March 31, 2019, not $4.06 50% June 30, 2019 June 30, 2020, $100,000, December 31, 2017, $270,000 As detailed further below, Saint-Gobain may $0.50 · Maturity of the Note 75 may, not · Change of Control may, not · Default may, not Subject to the aforementioned conversion rights of Saint-Gobain, the Company may Convertible Note Payable to Pharmstandard. June 15, 2017, $6.0 The Company issued the Pharmstandard Note on June 21, 2017, fifth 9.5% may In addition, at Pharmstandard’s election, Pharmstandard may $10.00. not 39.9% 39.9% may not Pharmstandard is the Company’s largest stockholder, and beneficially owned, in the aggregate, shares representing approximately 17.3% February 28, 2018. two Venture Loan Facility. September 2014, $25.0 two $12.5 The Company borrowed the first $12.5 September 2014 second $12.5 August 2015. 9.25% one 0.50% 8.75% one not 10.75%. The Company incurred $0.4 December 31, 2017 The Company made payments with respect to the first $12.5 October 31, 2016, first September 30, 2018. first $0.6 September 30, 2018, $0.6 first second $12.5 18 February 7, 2017, 24 second February 7, 2019. $0.6 February 7, 2019, $0.6 second 3% 24 2% 24 36 1% 36 On March 3, 2017, March 6, 2017, $23.1 five 5,000 $26.00 $23.1 $0.2 December 31, 2017 $1.25 $0.6 Upon the payment of the $23.1 In connection with the Loan Agreement, the Company issued to the Lenders and their affiliates warrants to purchase a total of 4,139 $181.20 second September 29, 2021 September 29, 2014, $0.3 December 31, 2017 Medinet Loan. December 2013, 13, $9.0 3.0% December 31, 2018. first not December 31, 2018, December 31, 2018 may $9.0 December 31, 2013, $6.9 8.0%, $2.1 During the year ended December 31, 2015, $1.0 $0.8 $0.2 December 31, 2016, $2.0 $1.5 $0.5 December 31, 2017, $2.0 $1.5 $0.5 December 31, 2016, $6.4 $1.8 December 31, 2017, $5.0 $1.9 December 31, 2016 2017, $5.4 $6.9 13 Other Notes. November 2013, $77,832 $46,754, $30,972 $13,825 December 31, 2015, December 31, 2016 December 31, 2017, 8.31% 60

Note 7 - Manufacturing Research

Note 7 - Manufacturing Research and Development Obligation	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Research, Development, and Computer Software Disclosure [Text Block]	7. In October 2014, 30% $5.0 2017 2018. As of December 31, 2016, $8.2 $5.2 $2.3 $0.6 $3.7 On September 22, 2017, $0.5 57,142 $5.2 $8.3 $1.5 December 31, 2017.

Note 8 - Facility Lease Obligat

Note 8 - Facility Lease Obligation, Capital Lease Obligations, Assets Held for Sale and Sold	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	8. Centerpoint Lease Obligation In August 2014, 125,000 $1.7 The term of the Centerpoint Lease Agreement was 10 July 1, 2015. six five third $49,052 The Centerpoint Lease Agreement required the Company to provide TKC with a letter of credit. The Company provided the bank that issued the letter of credit on its behalf a security deposit of $1.3 $0.7 December 31, 2015 December 31, 2016 Under the Centerpoint Lease Agreement, the Company was involved in the construction of the building. To the extent the Company was involved with the structural improvements of the construction project or takes construction risk prior to the commencement of a lease, ASC 840 40 05 5 The initial recording of these assets and liabilities was classified as non-cash investing and financing items, respectively, for purposes of the Company’s consolidated statements of cash flows. Under the Centerpoint Lease Agreement, the Company had an option to purchase the property. In February 2015, $7.4 $1.7 October 31, 2016 not no As of December 31, 2016, 3, no $0.7 December 31, 2017. $7.9 December 31, 2016. $7.4 December 31, 2016. $18.3 December 31, 2017 ( 3 In November 2017, third $1.8 $1.8 December 31, 2017. no $0.7 Capital Lease Obligations In August 2016, two $32,948 128 $4.2 March 2027. $2.4 December 31, 2016 $0.1 December 31, 2017 ( 3 December 31, 2017.

Note 9 - Common Stock

Note 9 - Common Stock	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Issuance of Common Stock in 2017 At-the-Market Offering in 2017 In May 2015, $30 February 2018, $30 $45 may 415 1933, not no 3% December 31, 2017, 3,373,967 $15.5 3,982,865 $7.3 January 1, 2018 March 16, 2018. December 31, 2016, 43,634 $5.5 March 16, 2018, $15.8 Other Common Stock Issued in 2017 In lieu of paying certain annual cash bonuses for 2016, January 2017 25% 2016 January 13, 2017. 4,005 $0.4 100% April 17, 2017, December 31, 2017, 368 During the year ended December 31, 2017, 369,998 $1.4 43 $0.8 $0.5 28,689 December 31, 2017 $0.1 December 31, 2017, 91,923 January 2018. $14,848 December 31, 2017 January 2018. June 2017, one 2,333, $20,999 December 31, 2017. In September 2017, .57,142 In November 2017, 34,499 Issuance of Common Stock in 2016 PIPE Financing On March 4, 2016, $60 March 2016, $19.9 182,621 136,966 0.75 $108.875. second June 2016, $29.8 273,933 205,450 first $107.00 five In connection with entering into the securities purchase agreement, the Company entered into a registration rights agreement with the investors pursuant to which the Company registered for resale the shares issued in the financing and the shares issuable upon exercise of the warrants issued in the financing. Follow-On Public Offering On August 2, 2016, 454,545 340,909 August 2016 $110.00 one 0.75 August 2016 $110.00 August 2, 2021. $48.2 Other Common Stock Issued in 2016 In lieu of paying certain annual cash bonuses for 2015, January 2016 2015 January 8, 2016 $2.24 296,936 $665,137 100% November 20, 2016. For 2016, 2014 2016. December 31, 2016, 52,173 $288,999 During the year ended December 31, 2016, $169,504 $1,999, $171,503. December 31, 2016, $134,388 $37,115 December 31, 2016, 22,783 14,514 1,350 6,919 December 31, 2016. December 31, 2016, 21,848 one 12,744 9,104 December 31, 2016. Issuance of Common Stock in 2015 Lummy License Agreement In connection with the Company’s entry into the Lummy License Agreement (see Note 12 April 7, 2015, 50,000 $202.20. April 7, 2015 $171.40 18% $202.20 $10,110,000 $8,570,000 $1,540,000 The Lummy Entities have also agreed to purchase approximately $10.0 $20.0 31 50% March 4, 2016, no Cellscript Agreement On December 22, 2015, CD40L CD40L In consideration for these development and production services, the Company has agreed to pay Cellscript total fees of $4,600,000. $2,111,432 45,309 180

Note 10 - Warrants

Note 10 - Warrants	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Warrants [Text Block]	10. In March 2016, $19.9 182,621 136,966 $107.00. March 14, 2021 June 2016, $29.8 273,933 205,450 $107.00. June 29, 2021 June 2016, 2,803 $0.3 In August 2016, $50.0 454,545 340,909 $110.00 “August 2016 August 2, 2021 As discussed in Note 6 September 2014, second September 29, 2021 March 2017, five 5,000 $26.00 $87,100 December 31, 2017. All outstanding warrants were issued with an original life of five As of December 31, 2017, 689,661 Type of Warrant and Classification Date of Issuance Number of Shares Exercise Price Expiration Common stock - Equity 9/29/14 4,139 $ 181.20 9/29/21 Common stock - Equity 3/4/16 134,163 $ 107.00 3/4/21 Common stock - Equity 6/29/16 205,450 $ 107.00 6/29/21 Common stock - Liability 8/2/16 340,909 $ 110.00 8/02/21 Common stock - Equity 3/6/17 5,000 $ 26.00 3/06/22 The following warrants were issued in August 2016 December 31, 2017, August 2016 August 2016 August 2016 August 2016 Exercise price $ 110.00 Expiration date August 2, 2021 Total shares issuable on exercise 340,909 The fair value of the August 2016 five zero August 2016 August 2016 The assumptions used by the Company to determine the fair value of the August 2016 December 31, 2016 2017: December 31, 2016 December 31, 2017 Exercise price of warrants $ 110.00 $ 110.00 Closing underlying stock price on date of valuation $ 98.00 $ 3.00 Expected stock price volatility 84 % 112 % Expected life (in years) 4.58 3.58 Risk-free interest rate 1.93 % 2.04 % Expected dividend yield 0.0 % 0.0 % Valuation per common share underlying each warrant $ 61.38 $ 0.49 Total liability for warrants on the consolidated balance sheet $ 20,926,061 $ 167,636 Decrease in fair value in the years ended December 31, 2016 and 2017 1,007,352 $ 20,758,425 In 2013, 24,989 $116.40 March 31, 2018, not

Note 11 - Stock Options and Emp

Note 11 - Stock Options and Employee Stock Purchase Plan	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. 2014 2014 In January 2014, 2014 “2014 2014 570,746 first December 31, 2018 December 31, 2024, 250,000 four 4% At the July 28, 2017 2014 2014 300,000 may 2014 first December 31, 2024 134,548 2014 570,746 first December 31, 2018 December 31, 2024, 250,000 four 4% Also in January 2014, 2014 “2014 2014 2014 may 10% 2014 2014 Under the terms of the 2014 85% 85% first first September 2, 2014 February 27, 2015. first 652 85% first $196.60 February 27, 2015 $180.40, $54,508. second March 2, 2015 August 31, 2015. second 1,015 85% second $180.40 August 31, 2015 $124.20, $72,800. third September 1, 2015 February 29, 2016. third 1,814 85% third $124.80 $88.80 February 29, 2016, $107,455. fourth March 1, 2016 August 31, 2016. fourth 1,507 85% fourth $98.20 $99.00 August 31, 2016, $63,788. fifth September 1, 2016 February 28, 2017. fifth 428 85% $23.00 February 28, 2017, $30,064. sixth March 1, 2017 August 31, 2017. sixth 999 85% $4.00 August 31, 2017, $17,711. not September 1, 2017. Upon the exercise of stock options, vesting of other awards and purchase of shares through the 2014 2014 2014 2014 December 31, 2017, 252,898 2014 10,899 2014 The Company recorded the following share-based compensation expense: Year Ended December 31, 2015 2016 2017 Research and development $ 2,104,401 $ 2,818,618 $ 2,424,924 General and administrative 1,910,537 2,575,874 3,226,844 Restructuring costs — — 3,215,848 Total share-based compensation expense $ 4,014,938 $ 5,394,492 $ 8,867,616 Allocations to research and development and general and administrative expense are based upon the department to which the associated employee reported. No Valuation Assumptions for Stock Option Plans and the 2014 The stock-based compensation expense recognized for stock option plans was determined using the Black-Scholes option valuation model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The weighted average assumptions used were as follows: 2015 2016 2017 Risk-free interest rate 2.05 % 1.50 % 2.26 % Expected dividend yield 0 % 0 % 0 % Expected stock option term (in years) 7 7 7 Expected volatility 87 % 82 % 86 % The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant. The dividend yield percentage is zero not $115.20, $76.80 $72.91 December 31, 2015, 2016 2017, The share-based compensation expense recognized for the 2014 2015 2016 2017 Risk-free interest rate 0.07% - 0.26 % 0.47 - 0.50 % 0.69 - 0.79 % Expected dividend yield 0 % 0 % 0 % Expected ESPP rights term (in years) 0.5 0.5 0.5 Expected volatility 45% - 58 % 113% - 141 % 141% - 210 % Other Information for Stock Option Plans The following table summarizes the Company’s stock option activity during the year ended December 31, 2017: Number of Weighted Weighted Aggregate Outstanding as of December 31, 2016 245,141 $ 121.40 Granted 70,604 $ 95.38 Exercised — $ — Cancelled (46,231 ) $ 97.58 Outstanding as of December 31, 2017 269,514 $ 111.91 5.58 $ — Exercisable as of December 31, 2017 182,039 $ 117.01 4.14 $ — Vested and expected to vest as of December 31, 2017 262,778 $ 112.19 5.66 $ — The aggregate intrinsic value of stock options in the table above represents the difference between the $3.00 December 31, 2017 $3.00 zero December 31, 2017. Included in amounts in the table above, the Company granted performance-based options to three 6,495 $121.80 July 2014. three December 31, 2017. The following table summarizes information about the Company’s stock options as of December 31, 2017: Exercise Price or Range of Exercise Price Options Outstanding Weighted Average Options Exercisable $3.40 1,500 9.74 125 $27.00 to $99.00 87,411 5.74 44,601 $101.00 to $185.60 179,740 5.80 130,825 $217.22 to $221.80 800 6.87 800 $705.97 to $733.20 63 3.69 63 269,514 5.58 176,414 Stock options with a fair value of $3.4 $4.4 $7.4 December 31, 2015, 2016 2017, December 31, 2017, $6.0 $2.6 2018, $2.0 2019, $1.3 2020, $0.05 2021.

Note 12 - Collaboration Agreeme

Note 12 - Collaboration Agreements	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Long-term Contracts or Programs Disclosure [Text Block]	12. Pharmstandard License Agreement In August 2013, first may Under the terms of the license agreement, Pharmstandard licensed the Company rights to clinical data generated by Pharmstandard under the agreement and granted the Company an option to obtain an exclusive license outside of the Pharmstandard Territory to develop and commercialize improvements to the Company’s Arcelis technology generated by Pharmstandard under the agreement, a non-exclusive worldwide royalty-free license to Pharmstandard improvements to manufacture products using the Company’s Arcelis technology and a license to specified follow-on licensed products generated by Pharmstandard outside of the Pharmstandard Territory, each on terms to be negotiated upon the Company’s request for a license. In addition, Pharmstandard agreed to pay the Company pass-through royalties on net sales of all licensed products in the low single digits until it has generated a specified amount of aggregate net sales. Once the net sales threshold is achieved, Pharmstandard will pay the Company royalties on net sales of specified licensed products, including rocapuldencel-T, in the low double digits below 20%. twelfth first no third third The agreement will terminate upon expiration of the royalty term, upon which all licenses will become fully paid-up perpetual exclusive licenses. Either party may may third may In November 2013, 24,989 $116.40 not February 2014. Pharmstandard and Actigen Option Agreement On February 1, 2018, PD1 PD1 not one one PD1 $3.6 $8.5 PD1 ten first first $5.0 In consideration for the rights granted under the option agreement, the Company agreed to issue to Pharmstandard, on or before April 2, 2018, 169,014 thirty not sixty Green Cross License Agreement In July 2013, first may Under the terms of the license, Green Cross has agreed to pay the Company $0.5 $0.5 20% fifteenth first The agreement will terminate upon expiration of the royalty term, which is 15 first may may third Medinet License Agreement In December 2013, October 2014. $9.0 In addition, under this agreement, the Company granted Medinet an option to acquire a nonexclusive, royalty-bearing license under the Company’s Arcelis technology to sell in Japan rocapuldencel-T and other products for the treatment of mRCC. The Company refers to the option as the sale option and the license as the sale license. This option expired on April 30, 2016. may may not In consideration for the manufacturing license, Medinet paid the Company $1.0 $9.0 $9.0 $5.0 first first July 2015 $1.0 second June 2016 $2.0 third March 2017 $2.0 December 31, 2017 $4.0 In December 2013, $9.0 3.0% December 31, 2018. not December 31, 2018, December 31, 2018 may The Company recorded the initial $1.0 $9.0 December 31, 2013, $6.9 8.0%, $2.1 December 31, 2015, $1.0 $0.8 $0.2 December 31, 2016, $2.0 $1.5 $0.5 December 31, 2017, $2.0 $1.5 $0.5 December 31, 2016, $6.4 $1.8 December 31, 2017, $5.0 $1.9 December 31, 2016 2017, $5.4 $6.9 The agreement will terminate upon expiration of the royalty term, upon which all licenses will become fully paid up, perpetual non-exclusive licenses. Either party may may third Lummy License Agreement On April 7, 2015, first December 2016 October 2017. Under the terms of the License Agreement, the parties will share relevant data, and the Company will have a right to reference Lummy HK data for purposes of its development programs under the Arcelis technology. In addition, Lummy HK has granted to the Company an exclusive, royalty-free license under and to any and all Lummy HK improvements to the Arcelis technology conceived or reduced to practice by Lummy HK (“Lummy HK Improvements”) and Lummy HK data to develop and/or commercialize products (“Arcelis-Based Products”) outside the Territory, an exclusive, royalty-free license under and to any and all investigational new drug applications ("INDs") and other regulatory approvals and Lummy HK trademarks used for an Arcelis-Based Product to develop and/or commercialize an Arcelis-Based Product outside the Territory and a non-exclusive, worldwide, royalty-free license under any Lummy HK Improvements and Lummy HK data to manufacture Arcelis-Based Products anywhere in the world. Lummy HK has the right to reference the Company’s data, INDs and other regulatory filings and submissions for the purpose of developing and obtaining regulatory approval of Licensed Products in the Territory. Pursuant to the License Agreement, Lummy HK will pay the Company royalties on net sales and an aggregate of up to $22.3 10 first may may third Pursuant to the license agreement, Lummy HK paid the Company a $1.5 October 2017. $1.5

Note 13 - Commitments

Note 13 - Commitments	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Commitments Disclosure [Text Block]	13. The Company rents laboratory and office space and equipment under operating leases that expire in various years through 2023. December 31, 2017 2018 $ 602,177 2019 640,309 2020 656,272 2021 650,607 2022 376,205 Thereafter 29,699 Total minimum lease payments $ 2,955,269 Rent expense related to operating leases for the years ended December 31, 2015, 2016 2017 $536,932, $1,098,452 $1,296,280, The Company has entered into various licensing agreements with universities and other research institutions under which the Company receives substantially all rights of the inventors or co-assignee to produce and market technology protected by certain patents and patent applications. The Company also entered into various assignment agreements with a scientist under which the Company receives exclusive rights to produce and market technology protected by certain patents and patent applications. The Company is generally required to make royalty payments ranging from 1% 4% No may

Note 14 - Employee Benefit Plan

Note 14 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	14. The Company provides a retirement plan qualified under section 401 1986, may 21. 25% first 6% December 31, 2015, 2016 2017, $334,487, $350,646 $243,598,

Note 15 - Net Loss Per Share

Note 15 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	15. The following table presents the computation of basic and diluted net loss per share of common stock: Year Ended December 31, 2015 2016 2017 Net loss attributable to common stockholders $ (74,788,521 ) $ (53,028,110 ) $ (40,577,510 ) Weighted average common shares outstanding, basic and diluted 1,022,862 1,600,286 3,017,409 Net loss per share attributable to common stockholders, basic and diluted $ (73.12 ) $ (33.14 ) $ (13.45 ) The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive: Year Ended December 31, 2015 2016 2017 Stock options outstanding 157,451 211,509 283,443 Warrants outstanding 4,139 356,339 688,771 Convertible notes outstanding — — 518,382

Note 16 - Selected Quarterly Da

Note 16 - Selected Quarterly Data (Unaudited)	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Quarterly Financial Information [Text Block]	16. Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 146,429 $ 488,643 $ 146,756 $ 163,640 Operating expenses: Research and development 9,501,976 9,164,184 9,340,018 10,301,058 General and administrative 2,975,024 3,389,479 3,010,518 4,828,280 Impairment of property and equipment (1) — — — 741,114 Operating loss (12,330,571 ) (12,065,020 ) (12,203,780 ) (15,706,812 ) Other income (expense), net (489,617 ) (541,225 ) (43,061 ) 351,976 Net loss $ (12,820,188 ) $ (12,606,245 ) $ (12,246,841 ) $ (15,354,836 ) Net loss per share, basic and diluted $ (11.34 ) $ (9.67 ) $ (6.46 ) $ (7.45 ) Weighted average shares outstanding, basic and diluted 1,130,331 1,303,308 1,896,911 2,062,257 ( 1 Represents impairment loss on property and equipment held for sale in the three December 31, 2016; none Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 105,259 $ 69,693 $ 53,497 $ 1,670,949 Operating expenses: Research and development 7,913,829 5,120,952 4,550,353 4,070,962 General and administrative 3,962,891 2,679,867 2,879,011 2,661,466 Impairment of property and equipment (1) 27,204,349 — — 50,036 Restructuring costs (2) 5,008,292 344,474 679,013 — Gain on disposal of impaired property (3) — — — (2,767,540 ) Operating loss (43,984,102 ) (8,075,600 ) (8,054,880 ) (2,343,975 ) Other income (expense), net (4) 19,904,021 (463,011 ) 1,988,933 451,104 Net loss $ (24,080,081 ) $ (8,538,611 ) $ (6,065,947 ) $ (1,892,871 ) Net loss per share, basic and diluted $ (11.66 ) $ (4.13 ) $ (2.08 ) $ (0.38 ) Weighted average shares outstanding, basic and diluted 2,065,676 2,068,743 2,911,800 4,992,418 ( 1 Represents impairment loss on property and equipment held for sale in the three March 31, 2017 three December 31, 2017; none ( 2 Represents costs of a reduction-in-force and early termination of a lease agreement implemented in March 2017. ( 3 Represents a gain on sale of impaired property in the three December 31, 2017 ( 4 Primarily represents gain on change in value of warrants classified as liabilities of $20,357,323 three March 31, 2017 $1,506,901 $600,119 three September 30, 2017 December 31, 2017,

Note 17 - Legal Proceedings

Note 17 - Legal Proceedings	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Legal Matters and Contingencies [Text Block]	17. The Company is not not

Note 18 - Subsequent Events

Note 18 - Subsequent Events	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	18. On January 8, 2018, January 6, 2018, 375,000 $1,500,000. March 2018, $450,000. $1.05 On February 14, 2018, no no $5.8 2014 09 first 2018. 1, not

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	Deferred Tax Asset Valuation Allowance Information presented below is in thousands: Additions Balance at Charged to Charged to Increases Balance at Year Ended December 31, 2017 $ 102,594 $ (18,700 ) $ — $ — $ 83,894 Year Ended December 31, 2016 $ 84,903 $ 17,691 $ — $ — $ 102,594 Year Ended December 31, 2015 $ 68,197 $ 16,706 $ — $ — $ 84,903 (a) – Impact of providing full valuation allowance against all deferred tax assets since the Company could not not

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Going Concern The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has evaluated principal conditions and events that may one December 31, 2017, $372.6 December 31, 2017, $17.2 $9.6 $15.2 December 31, 2017 not may On March 3, 2017, March 6, 2017, $23.1 five 5,000 $26.00 $23.1 $23.1 In March 2017, $1.2 December 31, 2017. $3.2 December 31, 2017. In June 2017, $6.0 $6.0 In August 2017, $1.5 $0.85 third 2017 April 2018. In September 2017, $0.5 57,142 $5.2 $8.3 In November 2017, $0.5 34,499 $2.4 December 31, 2019. From June 2017 December 31, 2017, $15.5 March 16, 2018, $7.3 December 31, 2017. As of December 31, 2017, $15.2 $7.6 not 2018. may one one no may Until such time, if ever, as the Company can generate substantial product revenues, it expects to seek to raise additional funds through a combination of equity offerings, debt financings, government contracts, government and other third third no The consolidated financial statements include the accounts of the Company and DC Bio Corp., the Company’s Canadian wholly-owned subsidiary, an unlimited liability corporation incorporated in the Province of Nova Scotia. Significant intercompany transactions and accounts have been eliminated. On January 18, 2018, one twenty
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company and DC Bio Corp., the Company’s Canadian wholly-owned subsidiary, an unlimited liability corporation incorporated in the Province of Nova Scotia and Argos Therapeutics (Europe)S.à.r.l., the Company’s wholly-owned subsidiary, a société anonyme à responsabilité limitée incorporated in Luxembourg. Significant intercompany transactions and accounts have been eliminated.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three December 31, 2016 2017, $52,723,376 $14,688,838,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and short-term investments.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost and depreciated over their estimated useful lives using the straight-line method. Property and equipment held under capital leases and leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to income. Repairs and maintenance costs are expensed as incurred.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company evaluates its long-lived assets whenever significant events or changes in circumstances occur that indicate that the carrying amount of an asset may not $0.7 $27.3 December 31, 2016 2017, 3 No December 31, 2015.
Warrant Liability Policy [Policy Text Block]	Accounting for Outstanding Warrants as Liabilities The Company has outstanding warrants issued in August 2016 December 31, 2017 The fair value of warrants recorded as liabilities is measured using the Black-Scholes valuation model. Inherent in the Black-Scholes valuation model are assumptions related to expected stock price volatility, expected life, risk-free interest rate and dividend yield. The risk-free interest rate is based on the U.S. Treasury five zero
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, 605. The Company has entered into license agreements with collaborators. The terms of these agreements have included nonrefundable signing and licensing fees, as well as milestone payments and royalties on any future product sales developed by the collaborators under these licenses. The Company assesses these multiple elements in accordance with ASC 605, These collaboration agreements are accounted for in accordance with Accounting Standards Update (“ASU”) No. 2009 13, 605 2009 13. third not Whenever the Company determines that an arrangement should be accounted for as a single unit of accounting, the Company must determine the period over which the performance obligations will be performed and revenue will be recognized, to the extent this is determinable. If the Company cannot reasonably estimate, to the extent this is determinable, the timing and the level of effort to complete its performance obligations under the arrangement, then the Company recognizes revenue under the arrangement on a straight-line basis over the period that the Company expects to complete such performance obligations. The Company’s license agreements with Pharmstandard International S.A. (“Pharmstandard”), Green Cross Corp. (“Green Cross”), Medinet Co., Ltd. (“Medinet”), and Lummy (Hong Kong) Co. Ltd. (“Lummy HK”) provide for, and any future license agreements it may may not no The Company’s current license agreements with Pharmstandard, Green Cross, Medinet and Lummy HK provide for, and any future license agreements the Company may may not not no The Company records deferred revenue when payments are received in advance of the culmination of the earnings process. This revenue is recognized in future periods when the applicable revenue recognition criteria have been met. In September 2006, 004. $39.8 $38.4 $1.4 September 2010, September 2010. May 2013. $5.4 May 2013 September 2015. $0.5 September 18, 2014 2 004 June 29, 2016, July 31, 2018. not The Company recognizes revenue from reimbursements earned in connection with the NIH and NIAID contract as reimbursable costs are incurred. The Company recognizes revenues from the achievement of milestones under the NIH and NIAID contract upon the accomplishment of any such milestone. For the years ended December 31, 2015, 2016 2017, $448,273, $807,968 $177,926, $38.3 December 31, 2017 December 31, 2017, $1.5 December 31, 2016 2017, $136,140 $31,977, no
Income Tax, Policy [Policy Text Block]	Income Taxes The Company provides for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not not
Segment Reporting, Policy [Policy Text Block]	Segment and Geographic Information Operating segments are defined as components of an enterprise engaging in business activities from which it may one
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs include all direct costs related to the development of the Company’s technology, including salaries and related benefits of research and development (“R&D”) personnel, depreciation of laboratory equipment, fees paid to consultants and contract research organizations, share-based compensation for R&D personnel, sponsored research payments and license fees. R&D costs are expensed as incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Compensation The Company estimates the grant date fair value of its share-based awards and amortizes this fair value to compensation expense over the requisite service period or vesting term (see Note 11
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) ASC 220, Comprehensive Income,
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation Gains and losses from foreign currency transactions are reflected in income currently. The Company has identified the functional currency of its subsidiaries with foreign operations as the applicable local currency. The translation from the applicable local currency to United States dollars is performed using the exchange rate in effect as of the balance sheet date. Revenue and expense accounts are translated using the average exchange rate experienced during the period. Adjustments resulting from the translation of the Company’s subsidiaries’ financial statements from its functional currency to the United States dollar are not
Interest Expense, Policy [Policy Text Block]	Interest Expense During the years ended December 31, 2015, 2016 2017, $23.1 March 2017, November 2017 ( 6 8
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements Not In May 2014, 2014 09 , Revenue from Contracts with Customers (“ASU 2014 09” 2014 09 not December 15, 2016. August 2015, 2015 14, Revenue from Contracts with Customers: Deferral of the Effective Date, 2014 09 one December 15, 2017, not first 2018. 2016 10, Identifying Performance Obligations and Licensing, two 2014 09 The Company plans to adopt the full retrospective method effective January 1, 2018, third no first 2018 In August 2016, ASU 2016 15, Statement of Cash Flows (Topic 230 entation of certain items in the statement of cash flows including but not December 15, 2017, January 1, 2018. In February 2016, 2016 02, Leases (Topic 842 2016 02" 2016 02 not 12 12 842 840 Leases December 15, 2018, January 1, 2019. In November 2016, 2016 18, Restricted Cash 2016 18" 2016 18 2016 18 first 2019, 2016 18 not Recently Adopted Accounting Standards In August 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09” 2016 09 December 31, 2017 no

Note 2 - Fair Value of Financ28

Note 2 - Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 45,389,314 $ — $ — $ 45,389,314 Restricted cash – long-term 740,000 — — 740,000 Total assets at fair value $ 46,129,314 $ — $ — $ 46,129,314 Liabilities Warrants $ — $ — $ 20,926,061 $ 20,926,061 Total liabilities at fair value $ — $ — $ 20,926,061 $ 20,926,061 Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 4,098,037 $ — $ — $ 4,098,037 Total assets at fair value $ 4,098,037 $ — $ — $ 4,098,037 Liabilities Warrants $ — $ — $ 167,636 $ 167,636 Total liabilities at fair value $ — $ — $ 167,636 $ 167,636
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Balance as of December 31, 2015 $ — Issuance of warrants at fair value 21,933,413 Unrealized gain during the year (1,007,352 ) Balance as of December 31, 2016 $ 20,926,061 Unrealized gain during the year (20,758,425 ) Balance as of December 31, 2017 $ 167,636
Financial Instruments [Table Text Block]	As of December 31, 2016 Amortized Cost Gross Gross Aggregate Money-market funds $ 45,389,314 $ — $ — $ 45,389,314 Restricted cash – long-term 740,000 — — 740,000 $ 46,129,314 $ — $ — $ 46,129,314 As of December 31, 2017 Amortized Cost Gross Gross Aggregate Money-market funds $ 4,098,037 $ — $ — $ 4,098,037 $ 4,098,037 $ — $ — $ 4,098,037

Note 3 - Restructuring Activi29

Note 3 - Restructuring Activities and Related Impairments of Property and Equipment and Leases (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Severance and Lease and Other Total Balance as of December 31, 2016 $ — $ — $ — Restructuring costs 4,416,189 1,615,590 6,031,779 Acceleration of stock options and restricted stock (3,171,751 ) — (3,171,751 ) Cash payments (1,244,438 ) (1,615,590 ) (2,860,028 ) Balance as of December 31, 2017 $ — $ — $ —

Note 4 - Property and Equipme30

Note 4 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	Useful Life 2016 2017 Office furniture and equipment 7 $ 657,875 $ 639,603 Computer equipment 3 1,018,173 989,137 Computer software 3 3,146,978 3,146,978 Laboratory equipment 7 5,709,215 6,050,640 Leasehold improvements 5 2,435,530 2,435,530 Assets related to facility lease obligation 8,070,033 — Construction-in-progress 28,807,957 — Total property and equipment, net 49,845,761 13,261,888 Less: Accumulated depreciation and amortization (8,894,184 ) (9,679,565 ) Property and equipment, net $ 40,951,577 $ 3,582,323
Depreciation and Amortization Expense [Member]
Notes Tables
Property, Plant and Equipment [Table Text Block]	Year ended December 31, 2015 $ 680,444 Year ended December 31, 2016 $ 952,341 Year ended December 31, 2017 $ 967,891

Note 5 - Income Taxes (Tables)

Note 5 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2016 2017 U.S. federal and state net operating loss carryforwards $ 89,445,428 $ 69,850,442 Foreign net operating loss carryforwards 1,526,207 1,649,765 Contribution carryforwards 4,245 2,202 Research and development credits 7,705,933 8,477,318 Investment tax credits 30,363 32,473 Share-based compensation 1,586,780 2,725,223 Other accruals 917,376 84,357 Deferred revenue 1,120,772 1,044,788 Property and equipment 257,192 27,628 Total deferred tax assets 102,594,296 83,894,196 Valuation allowance for deferred assets (102,594,296 ) (83,894,196 ) Net deferred tax assets $ — $ —
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2015 2016 2017 Amount Percent of Pretax Earnings Amount Percent of Pretax Earnings Amount Percent of Pretax Earnings U.S. federal tax statutory rate $ (25,428,097 ) 34.0 % $ (18,029,558 ) 34.0 % $ (13,796,353 ) 34.0 % State taxes (net of federal benefit) (1,936,719 ) 2.6 % (1,034,566 ) 2.0 % (801,406 ) 2.0 % U.S. federal research and development tax credits (2,135,940 ) 2.9 % (1,368,171 ) 2.6 % (1,038,768 ) 2.6 % Other nondeductible expenses 1,032,480 (1.4 %) 760,287 (1.5 %) 1,973,462 (4.9 %) Increase in unrecognized tax benefits 640,782 (0.9 %) 410,451 (0.8 %) 311,630 (0.8 %) Change in effective state tax rate 1,190,519 (1.6 %) 1,655,991 (3.1 %) 12,871 (0.0 %) Expiration of NOL & contribution carryforwards 9,590,101 (12.8 %) — (0.0 %) 136,325 (0.3 %) Adjustment for change in federal effective tax rate — (0.0 %) — (0.0 %) 41,255,460 (101.7 %) Change in fair value of warrant liability — (0.0 %) — (0.0 %) (7,467,843 ) 18.4 % Change in valuation allowance 16,705,784 (22.3 %) 17,691,710 (33.4 %) (18,700,100 ) 46.1 % Deferred tax asset true-ups 341,090 (0.5 %) (86,144 ) 0.2 % (1,885,278 ) 4.6 % Provision for income taxes $ — 0.0 % $ — 0.0 % $ — 0.0 %
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	2015 2016 2017 Beginning balance $ 2,155,000 $ 2,795,800 $ 3,206,300 Gross increase for tax positions related to current periods 640,800 410,500 311,600 Gross (decrease) increase for tax positions related to prior periods — — — Ending balance $ 2,795,800 $ 3,206,300 $ 3,517,900

Note 6 - Notes Payable and Co32

Note 6 - Notes Payable and Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Debt [Table Text Block]	December 31, December 31, Notes payable under the venture loan and security agreement, including accrued interest 24,035,029 $ — Less debt discount and debt issuance costs (320,409 ) — Notes payable under the venture loan and security agreement, net 23,714,620 — Convertible note payable to Pharmstandard, including accrued interest — 6,302,959 Convertible note payable to Invetech, including accrued interest — 5,845,655 Convertible note payable to Saint-Gobain, including accrued interest — 2,334,929 Note payable to Medinet, including accrued interest 6,403,186 4,958,824 Other notes payable 30,972 13,825 Total debt 30,148,778 19,456,192 Less current portion of convertible note payable to Invetech, including accrued interest — (1,300,000 ) Less current portion of convertible note payable to Saint-Gobain, including accrued interest — (1,050,000 ) Less current portion of note payable to Medinet, including accrued interest — (4,958,824 ) Less current portion of other notes payable (11,475,480 (13,825 ) Long-term portion of notes payable and convertible notes payable $ 18,673,298 12,133,543

Note 10 - Warrants (Tables)

Note 10 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Type of Warrant and Classification Date of Issuance Number of Shares Exercise Price Expiration Common stock - Equity 9/29/14 4,139 $ 181.20 9/29/21 Common stock - Equity 3/4/16 134,163 $ 107.00 3/4/21 Common stock - Equity 6/29/16 205,450 $ 107.00 6/29/21 Common stock - Liability 8/2/16 340,909 $ 110.00 8/02/21 Common stock - Equity 3/6/17 5,000 $ 26.00 3/06/22
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	December 31, 2016 December 31, 2017 Exercise price of warrants $ 110.00 $ 110.00 Closing underlying stock price on date of valuation $ 98.00 $ 3.00 Expected stock price volatility 84 % 112 % Expected life (in years) 4.58 3.58 Risk-free interest rate 1.93 % 2.04 % Expected dividend yield 0.0 % 0.0 % Valuation per common share underlying each warrant $ 61.38 $ 0.49 Total liability for warrants on the consolidated balance sheet $ 20,926,061 $ 167,636 Decrease in fair value in the years ended December 31, 2016 and 2017 1,007,352 $ 20,758,425
August 2016, Warrant [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	August 2016 Exercise price $ 110.00 Expiration date August 2, 2021 Total shares issuable on exercise 340,909

Note 11 - Stock Options and E34

Note 11 - Stock Options and Employee Stock Purchase Plan (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended December 31, 2015 2016 2017 Research and development $ 2,104,401 $ 2,818,618 $ 2,424,924 General and administrative 1,910,537 2,575,874 3,226,844 Restructuring costs — — 3,215,848 Total share-based compensation expense $ 4,014,938 $ 5,394,492 $ 8,867,616
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2015 2016 2017 Risk-free interest rate 2.05 % 1.50 % 2.26 % Expected dividend yield 0 % 0 % 0 % Expected stock option term (in years) 7 7 7 Expected volatility 87 % 82 % 86 % 2015 2016 2017 Risk-free interest rate 0.07% - 0.26 % 0.47 - 0.50 % 0.69 - 0.79 % Expected dividend yield 0 % 0 % 0 % Expected ESPP rights term (in years) 0.5 0.5 0.5 Expected volatility 45% - 58 % 113% - 141 % 141% - 210 %
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Weighted Weighted Aggregate Outstanding as of December 31, 2016 245,141 $ 121.40 Granted 70,604 $ 95.38 Exercised — $ — Cancelled (46,231 ) $ 97.58 Outstanding as of December 31, 2017 269,514 $ 111.91 5.58 $ — Exercisable as of December 31, 2017 182,039 $ 117.01 4.14 $ — Vested and expected to vest as of December 31, 2017 262,778 $ 112.19 5.66 $ —
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Exercise Price or Range of Exercise Price Options Outstanding Weighted Average Options Exercisable $3.40 1,500 9.74 125 $27.00 to $99.00 87,411 5.74 44,601 $101.00 to $185.60 179,740 5.80 130,825 $217.22 to $221.80 800 6.87 800 $705.97 to $733.20 63 3.69 63 269,514 5.58 176,414

Note 13 - Commitments (Tables)

Note 13 - Commitments (Tables)	12 Months Ended
	Dec. 31, 2017
Laboratory and Office Space and Equipment [Member]
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2018 $ 602,177 2019 640,309 2020 656,272 2021 650,607 2022 376,205 Thereafter 29,699 Total minimum lease payments $ 2,955,269

Note 15 - Net Loss Per Share (T

Note 15 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2015 2016 2017 Net loss attributable to common stockholders $ (74,788,521 ) $ (53,028,110 ) $ (40,577,510 ) Weighted average common shares outstanding, basic and diluted 1,022,862 1,600,286 3,017,409 Net loss per share attributable to common stockholders, basic and diluted $ (73.12 ) $ (33.14 ) $ (13.45 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2015 2016 2017 Stock options outstanding 157,451 211,509 283,443 Warrants outstanding 4,139 356,339 688,771 Convertible notes outstanding — — 518,382

Note 16 - Selected Quarterly 37

Note 16 - Selected Quarterly Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Quarterly Financial Information [Table Text Block]	Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 146,429 $ 488,643 $ 146,756 $ 163,640 Operating expenses: Research and development 9,501,976 9,164,184 9,340,018 10,301,058 General and administrative 2,975,024 3,389,479 3,010,518 4,828,280 Impairment of property and equipment (1) — — — 741,114 Operating loss (12,330,571 ) (12,065,020 ) (12,203,780 ) (15,706,812 ) Other income (expense), net (489,617 ) (541,225 ) (43,061 ) 351,976 Net loss $ (12,820,188 ) $ (12,606,245 ) $ (12,246,841 ) $ (15,354,836 ) Net loss per share, basic and diluted $ (11.34 ) $ (9.67 ) $ (6.46 ) $ (7.45 ) Weighted average shares outstanding, basic and diluted 1,130,331 1,303,308 1,896,911 2,062,257 Quarter Ended March 31, June 30, September 30, December 31, Revenue $ 105,259 $ 69,693 $ 53,497 $ 1,670,949 Operating expenses: Research and development 7,913,829 5,120,952 4,550,353 4,070,962 General and administrative 3,962,891 2,679,867 2,879,011 2,661,466 Impairment of property and equipment (1) 27,204,349 — — 50,036 Restructuring costs (2) 5,008,292 344,474 679,013 — Gain on disposal of impaired property (3) — — — (2,767,540 ) Operating loss (43,984,102 ) (8,075,600 ) (8,054,880 ) (2,343,975 ) Other income (expense), net (4) 19,904,021 (463,011 ) 1,988,933 451,104 Net loss $ (24,080,081 ) $ (8,538,611 ) $ (6,065,947 ) $ (1,892,871 ) Net loss per share, basic and diluted $ (11.66 ) $ (4.13 ) $ (2.08 ) $ (0.38 ) Weighted average shares outstanding, basic and diluted 2,065,676 2,068,743 2,911,800 4,992,418

Schedule II - Valuation and Q38

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Summary of Valuation Allowance [Table Text Block]	Additions Balance at Charged to Charged to Increases Balance at Year Ended December 31, 2017 $ 102,594 $ (18,700 ) $ — $ — $ 83,894 Year Ended December 31, 2016 $ 84,903 $ 17,691 $ — $ — $ 102,594 Year Ended December 31, 2015 $ 68,197 $ 16,706 $ — $ — $ 84,903

Note 1 - Organization and Acc39

Note 1 - Organization and Accounting Policies (Details Textual)	Jan. 18, 2018	Nov. 22, 2017USD ($)shares	Sep. 22, 2017USD ($)shares	Mar. 06, 2017USD ($)$ / sharesshares	Apr. 07, 2015USD ($)	Sep. 18, 2014USD ($)	Nov. 30, 2017shares	Sep. 30, 2017shares	Mar. 09, 2018USD ($)	Dec. 31, 2017USD ($)shares	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Dec. 31, 2017USD ($)shares	Aug. 31, 2017USD ($)	Jun. 15, 2017USD ($)	Dec. 31, 2014USD ($)
Retained Earnings (Accumulated Deficit)										$ (372,564,327)				$ (331,986,817)					$ (372,564,327)	$ (331,986,817)			$ (372,564,327)
Assets, Current										17,184,421				55,501,794					17,184,421	55,501,794			17,184,421
Liabilities, Current										9,557,166				30,609,838					9,557,166	30,609,838			9,557,166
Cash and Cash Equivalents, at Carrying Value										$ 15,188,838				52,973,376					$ 15,188,838	52,973,376	$ 6,163,144		$ 15,188,838			$ 37,223,590
Extinguishment of Debt, Amount				$ 23,100,000
Class of Warrant or Right, Term				5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				5,000						689,661									689,661				689,661
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 26
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost																			$ 3,171,751
Proceeds from Issuance of Common Stock					$ 10,110,000
Working Capital										$ 7,600,000									7,600,000				$ 7,600,000
Cash, Uninsured Amount										14,688,838				52,723,376					14,688,838	52,723,376			14,688,838
Impairment of Long-Lived Assets Held-for-use																			$ 27,300,000	700,000	0
Fair Value Assumptions, Expected Dividend Rate																			0.00%
Revenues										1,670,949	$ 53,497	$ 69,693	$ 105,259	163,640	$ 146,756	$ 488,643	$ 146,429		$ 1,899,398	945,468	518,329
Provision for Other Credit Losses																			$ 0
Number of Operating Segments																			1
NIH & NIAID [Member]
Unattained Funds, Contracted Commitment										39,800,000									$ 39,800,000				39,800,000
Additional Unattained Funds, Contracted Commitment						$ 500,000																$ 5,400,000
Revenues																			177,926	807,968	$ 448,273		38,300,000
Remaining Unattained Funds Contracted Commitment										1,500,000									1,500,000				1,500,000
Accounts Receivable, Net, Current										31,977				$ 136,140					31,977	136,140			31,977
NIH & NIAID [Member] | Operating Expense [Member]
Unattained Funds, Contracted Commitment										38,400,000									38,400,000				38,400,000
NIH & NIAID [Member] | Other Specified [Member]
Unattained Funds, Contracted Commitment										$ 1,400,000									$ 1,400,000				$ 1,400,000
Warrants Issued in August 2016 [Member]
Fair Value Assumptions, Expected Dividend Rate																			0.00%
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20
Extinguishment of Research and Development Obligation to Invetech [Member]
Extinguishment of Debt, Amount			$ 8,300,000
Repayments of Long-term Debt			$ 500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares			57,142					57,142
Extinguishment of Research and Development Obligation to Saint-Gobain [Member]
Repayments of Long-term Debt		$ 500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares		34,499					34,499
Medpace, Inc. [Member]
Research and Development Obligation Deferred Fees																								$ 1,500,000
Payment of Research and Development Obligation											$ 850,000
Sales Agreement, At-the-market Offering [Member]
Proceeds from Issuance of Common Stock																		$ 6,000,000	$ 15,500,000	$ 5,500,000
Sales Agreement, At-the-market Offering [Member] | Subsequent Event [Member]
Proceeds from Issuance of Common Stock									$ 7,300,000
Convertible Note Payable to Pharmstandard [Member]
Debt Instrument, Face Amount												$ 6,000,000						$ 6,000,000							$ 6,000,000
Convertible Note Payable to Invetech Pty Ltd [Member]
Debt Instrument, Face Amount			$ 5,200,000
Convertible Promissory Note to Saint-Gobain [Member]
Debt Instrument, Face Amount		$ 2,360,000
Employee Severance [Member]
Severance Costs																			1,200,000
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost																			$ 3,171,751
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 26
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares																			91,643

Note 2 - Fair Value of Financ40

Note 2 - Fair Value of Financial Instruments (Details Textual) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Long-term Debt, Fair Value	$ 19,100,000	$ 29,800,000
Long-term Debt	$ 19,456,192	$ 30,148,778

Note 2 - Fair Value of Financ41

Note 2 - Fair Value of Financial Instruments - Fair Value of Financial Instruments (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Assets at fair value	$ 4,098,037	$ 46,129,314
Liabilities at fair value	167,636	20,926,061
Warrant Liabilities [Member]
Liabilities at fair value	167,636	20,926,061
Fair Value, Inputs, Level 1 [Member]
Assets at fair value	4,098,037	46,129,314
Liabilities at fair value
Fair Value, Inputs, Level 1 [Member] | Warrant Liabilities [Member]
Liabilities at fair value
Fair Value, Inputs, Level 2 [Member]
Assets at fair value
Liabilities at fair value
Fair Value, Inputs, Level 2 [Member] | Warrant Liabilities [Member]
Liabilities at fair value
Fair Value, Inputs, Level 3 [Member]
Assets at fair value
Liabilities at fair value	167,636	20,926,061
Fair Value, Inputs, Level 3 [Member] | Warrant Liabilities [Member]
Liabilities at fair value	167,636	20,926,061
Money Market Funds [Member]
Assets at fair value	4,098,037	45,389,314
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets at fair value	4,098,037	45,389,314
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets at fair value
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets at fair value
Restricted Cash, Long-Term [Member]
Assets at fair value		740,000
Restricted Cash, Long-Term [Member] | Fair Value, Inputs, Level 1 [Member]
Assets at fair value		740,000
Restricted Cash, Long-Term [Member] | Fair Value, Inputs, Level 2 [Member]
Assets at fair value
Restricted Cash, Long-Term [Member] | Fair Value, Inputs, Level 3 [Member]
Assets at fair value

Note 2 - Fair Value of Financ42

Note 2 - Fair Value of Financial Instruments - Changes in Fair Value for Warrants (Details) - Warrant Liability [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Balance	$ 20,926,061
Issuance of warrants at fair value		21,933,413
Unrealized gain during the year	(20,758,425)	(1,007,352)
Balance	$ 167,636	$ 20,926,061

Note 2 - Fair Value of Financ43

Note 2 - Fair Value of Financial Instruments - Financial Instruments (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Amortized Cost Basis	$ 4,098,037	$ 46,129,314
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Aggregate Fair Value	4,098,037	46,129,314
Money Market Funds [Member]
Amortized Cost Basis	4,098,037	45,389,314
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Aggregate Fair Value	$ 4,098,037	45,389,314
Restricted Cash, Long-Term [Member]
Amortized Cost Basis		740,000
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Aggregate Fair Value		$ 740,000

Note 3 - Restructuring Activi44

Note 3 - Restructuring Activities and Related Impairments of Property and Equipment and Leases (Details Textual)

Mar. 10, 2017

Apr. 30, 2017USD ($)

Mar. 31, 2017USD ($)

Jan. 31, 2017USD ($)

Dec. 31, 2017USD ($)

Sep. 30, 2017USD ($)

Jun. 30, 2017USD ($)

Mar. 31, 2017USD ($)

Dec. 31, 2016USD ($)

[3]

Sep. 30, 2016USD ($)

[3]

Jun. 30, 2016USD ($)

[3]

Mar. 31, 2016USD ($)

[3]

Dec. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Mar. 17, 2017USD ($)

Restructuring Charges

[1]

$ 679,013

[1]

$ 344,474

[1]

$ 5,008,292

[1]

$ 6,031,779

Impairment of Long-Lived Assets to be Disposed of

50,036

[2]

[2]

[2]

27,204,349

[2]

$ 741,114

27,254,385

741,114

Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost

3,171,751

Proceeds from Sale of Property, Plant, and Equipment

3,250,631

Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property

$ 2,767,540

[4]

[4]

[4]

[4]

2,767,540

Construction in Progress [Member]

Impairment of Long-Lived Assets to be Disposed of

6,100,000

Centerpoint Facility [Member]

Proceeds from Sale of Property, Plant, and Equipment

1,800,000

Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property

1,800,000

Restructuring Charges [Member]

Lease Termination Fee

1,600,000

CTI Facility [Member]

Lessee, Operating Lease, Term of Contract

10 years

Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms

2

Security Deposit

$ 2,400,000

$ 2,400,000

Lessee, Operating Lease, Interest Rate Per Annum

12.00%

Payments for Unpaid Construction

$ (1,700,000)

$ (700,000)

Lease Arrangement, Refund of Security Deposit

$ 100,000

Lessee, Operating Lease, Renewal Term

5 years

CTI Facility [Member] | Construction in Progress [Member]

Impairment of Long-Lived Assets to be Disposed of

900,000

Centerpoint Facility [Member] | Construction in Progress [Member]

Impairment of Long-Lived Assets to be Disposed of

18,300,000

Centerpoint Facility [Member] | Facility [Member]

Impairment of Long-Lived Assets to be Disposed of

700,000

Employee Severance [Member]

Restructuring Charges

$ 4,416,189

Restructuring and Related Cost, Number of Positions Eliminated

46

Restructuring and Related Cost, Number of Positions Eliminated, Period Percent

38.00%

Number of Employees before Restructuring

122

Number of Employees after Restructuring

76

39

39

Severance Costs

$ 1,200,000

Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost

$ 3,171,751

[1]

Represents costs of a reduction-in-force and early termination of a lease agreement implemented in March 2017.

[2]

Represents impairment loss on property and equipment held for sale in the three months ended March 31, 2017 and three months ended December 31, 2017; none present in other periods presented.

[3]

Represents impairment loss on property and equipment held for sale in the three months ended December 31, 2016; none present in other periods presented.

[4]

Represents a gain on sale of impaired property in the three months ended December 31, 2017 from the disposal of the Centerpoint property and certain other property in the Saint-Gobain debt restructuring.

Note 3 - Restructuring Activi45

Note 3 - Restructuring Activities and Related Impairments of Property and Equipment and Leases - Restructuring Liability (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2017		Sep. 30, 2017	[1]	Jun. 30, 2017	[1]	Mar. 31, 2017		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Balance
Restructuring costs		[1]	$ 679,013		$ 344,474		5,008,292	[1]	6,031,779
Acceleration of stock options and restricted stock									(3,171,751)
Cash payments									(2,860,028)
Balance
Employee Severance [Member]
Balance
Restructuring costs									4,416,189
Acceleration of stock options and restricted stock									(3,171,751)
Cash payments									(1,244,438)
Balance
Facility Closing [Member]
Balance
Restructuring costs									1,615,590
Acceleration of stock options and restricted stock
Cash payments									(1,615,590)
Balance
[1]	Represents costs of a reduction-in-force and early termination of a lease agreement implemented in March 2017.

Note 4 - Property and Equipme46

Note 4 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended																12 Months Ended
	Dec. 31, 2017		Sep. 30, 2017		Jun. 30, 2017		Mar. 31, 2017		Dec. 31, 2016		Sep. 30, 2016	[2]	Jun. 30, 2016	[2]	Mar. 31, 2016	[2]	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Assets Held-for-sale, Not Part of Disposal Group, Current	$ 600,000								$ 1,452,172								$ 600,000	$ 1,452,172
Impairment of Long-Lived Assets to be Disposed of	50,036	[1]		[1]		[1]	$ 27,204,349	[1]	741,114	[2]							27,254,385	741,114
Proceeds from Sale of Property, Plant, and Equipment																	3,250,631
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	2,767,540	[3]		[3]		[3]		[3]									2,767,540
Property, Plant and Equipment, Gross	13,261,888								49,845,761								13,261,888	49,845,761
Various Equipment [Member]
Assets Held-for-sale, Not Part of Disposal Group, Current	700,000																700,000
Impairment of Long-Lived Assets to be Disposed of																	1,100,000
Construction in Progress [Member]
Impairment of Long-Lived Assets to be Disposed of																	6,100,000
Property, Plant and Equipment, Gross									28,807,957									28,807,957
Accumulated Capitalized Interest Costs	0								2,700,000								0	2,700,000
Construction in Progress [Member] | Centerpoint Facility [Member]
Impairment of Long-Lived Assets to be Disposed of																	18,300,000
Construction in Progress [Member] | Power Generation Agreements [Member]
Impairment of Long-Lived Assets to be Disposed of																	100,000
Property, Plant and Equipment, Gross	$ 0								2,400,000								0	2,400,000
Isolator Machines [Member]
Impairment of Long-Lived Assets to be Disposed of																		741,114
Assets Held-for-sale, Not Part of Disposal Group									$ 1,452,172									$ 1,452,172
Centerpoint Facility [Member]
Proceeds from Sale of Property, Plant, and Equipment																	1,800,000
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property																	$ 1,800,000
[1]	Represents impairment loss on property and equipment held for sale in the three months ended March 31, 2017 and three months ended December 31, 2017; none present in other periods presented.
[2]	Represents impairment loss on property and equipment held for sale in the three months ended December 31, 2016; none present in other periods presented.
[3]	Represents a gain on sale of impaired property in the three months ended December 31, 2017 from the disposal of the Centerpoint property and certain other property in the Saint-Gobain debt restructuring.

Note 4 - Property and Equipme47

Note 4 - Property and Equipment - Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property and equipment, gross	$ 13,261,888	$ 49,845,761
Less: Accumulated depreciation and amortization	(9,679,565)	(8,894,184)
Property and equipment, net	$ 3,582,323	40,951,577
Office Furniture and Equipment [Member]
Useful Life (Year)	7 years
Property and equipment, gross	$ 639,603	657,875
Computer Equipment [Member]
Useful Life (Year)	3 years
Property and equipment, gross	$ 989,137	1,018,173
Computer Software [Member]
Useful Life (Year)	3 years
Property and equipment, gross	$ 3,146,978	3,146,978
Laboratory Equipment [Member]
Useful Life (Year)	7 years
Property and equipment, gross	$ 6,050,640	5,709,215
Leasehold Improvements [Member]
Useful Life (Year)	5 years
Property and equipment, gross	$ 2,435,530	2,435,530
Assets Held under Capital Leases [Member]
Property and equipment, gross		8,070,033
Construction in Progress [Member]
Property and equipment, gross		$ 28,807,957

Note 4 - Property and Equipme48

Note 4 - Property and Equipment - Depreciation and Amortization Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Year ended December 31, 2015	$ 967,891	$ 952,341	$ 680,444

Note 5 - Income Taxes (Details

Note 5 - Income Taxes (Details Textual) - USD ($)	Jun. 28, 2017	Aug. 04, 2016	Sep. 18, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Expense (Benefit)					$ 0	$ 0	$ 0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount					18,700,100
Undistributed Earnings of Foreign Subsidiaries					$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent					34.00%	34.00%	34.00%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent					2.00%	2.00%	2.60%
Deferred Tax Assets, Gross, Changes due to Tax Act					$ (41,300,000)
Unrecognized Tax Benefits					3,517,900	$ 3,206,300	$ 2,795,800	$ 2,155,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued					0	$ 0
Remeasured Deferred Tax Assets due to Tax Act [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount					(41,300,000)
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				21.00%
Tax Year 2015 [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			$ (1,190,500)
Tax Year 2017 [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ (16,810)	$ (1,656,000)
North Carolina Department of Revenue [Member] | Tax Year 2015 [Member]
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent			5.00%
North Carolina Department of Revenue [Member] | Tax Year 2016 [Member]
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent		3.00%	4.00%
North Carolina Department of Revenue [Member] | Tax Year 2017 [Member]
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent	2.50%
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards					300.80
Tax Credit Carryforward, Amount					8.20
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration					28,156,600
Domestic Tax Authority [Member] | Canada Revenue Agency [Member]
Operating Loss Carryforwards					6.10
Tax Credit Carryforward, Amount					32,500
Domestic Tax Authority [Member] | Canadian Provincial [Member]
Operating Loss Carryforwards					6.10
Domestic Tax Authority [Member] | Luxembourg Inland Revenue [Member]
Operating Loss Carryforwards					0.20
State and Local Jurisdiction [Member]
Operating Loss Carryforwards					338.50
Tax Credit Carryforward, Amount					$ 0.30

Note 5 - Income Taxes - Signifi

Note 5 - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
U.S. federal and state net operating loss carryforwards	$ 69,850,442	$ 89,445,428
Foreign net operating loss carryforwards	1,649,765	1,526,207
Contribution carryforwards	2,202	4,245
Research and development credits	8,477,318	7,705,933
Investment tax credits	32,473	30,363
Share-based compensation	2,725,223	1,586,780
Other accruals	84,357	917,376
Deferred revenue	1,044,788	1,120,772
Property and equipment	27,628	257,192
Total deferred tax assets	83,894,196	102,594,296
Valuation allowance for deferred assets	(83,894,196)	(102,594,296)
Net deferred tax assets	$ 0	$ 0

Note 5 - Income Taxes - Effecti

Note 5 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
U.S. federal tax statutory rate	$ (13,796,353)	$ (18,029,558)	$ (25,428,097)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%	34.00%
State taxes (net of federal benefit)	$ (801,406)	$ (1,034,566)	$ (1,936,719)
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent	2.00%	2.00%	2.60%
U.S. federal research and development tax credits	$ (1,038,768)	$ (1,368,171)	$ (2,135,940)
U.S. federal research and development tax credits, percentage	2.60%	2.60%	2.90%
Other nondeductible expenses	$ 1,973,462	$ 760,287	$ 1,032,480
Other nondeductible expenses, percentage	(4.90%)	(1.50%)	(1.40%)
Increase in unrecognized tax benefits	$ 311,630	$ 410,451	$ 640,782
Increase in unrecognized tax benefits, percentage	(0.80%)	(0.80%)	(0.90%)
Change in effective state tax rate	$ 12,871	$ 1,655,991	$ 1,190,519
Change in effective state tax rate, percentage	0.00%	(3.10%)	(1.60%)
Expiration of NOL & contribution carryforwards	$ 136,325		$ 9,590,101
Expiration of NOL & contribution carryforwards, percentage	(0.30%)	0.00%	(12.80%)
Adjustment for change in federal effective tax rate	$ 41,255,460
Adjustment for change in federal effective tax rate, percentage	(101.70%)	0.00%	0.00%
Change in fair value of warrant liability	$ (7,467,843)
Change in fair value of warrant liability, percentage	18.40%	0.00%	0.00%
Change in valuation allowance	$ (18,700,100)	$ 17,691,710	$ 16,705,784
Change in valuation allowance, percentage	46.10%	(33.40%)	(22.30%)
Deferred tax asset true-ups	$ (1,885,278)	$ (86,144)	$ 341,090
Deferred tax asset true-ups, percentage	4.60%	0.20%	(0.50%)
Provision for income taxes	$ 0	$ 0	$ 0
Provision for income taxes, percentage	0.00%	0.00%	0.00%

Note 5 - Income Taxes - Change

Note 5 - Income Taxes - Change in Gross Unrecognized Tax Position (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Beginning balance	$ 3,206,300	$ 2,795,800	$ 2,155,000
Gross increase for tax positions related to current periods	311,600	410,500	640,800
Gross (decrease) increase for tax positions related to prior periods
Ending balance	$ 3,517,900	$ 3,206,300	$ 2,795,800

Note 6 - Notes Payable and Co53

Note 6 - Notes Payable and Convertible Notes Payable (Details Textual)	Feb. 28, 2018	Nov. 22, 2017USD ($)$ / sharesshares	Sep. 22, 2017USD ($)$ / sharesshares	Mar. 06, 2017USD ($)$ / sharesshares	Sep. 29, 2014USD ($)	Nov. 30, 2017shares	Sep. 30, 2017shares	Aug. 31, 2015USD ($)	Dec. 31, 2013USD ($)	Nov. 30, 2013USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Sep. 30, 2017	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2013USD ($)	Feb. 07, 2019USD ($)	Sep. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Jun. 21, 2017$ / shares	Jun. 15, 2017USD ($)	Apr. 07, 2015$ / shares
Stock Issued During Period, Value, Conversion of Convertible Securities														$ 340,000
Extinguishment of Debt, Amount				$ 23,100,000
Gain (Loss) on Extinguishment of Debt											$ 600,119	$ 1,506,901		$ 2,356,478
Share Price | $ / shares		$ 4.06									$ 3			$ 3									$ 171.40
Class of Warrant or Right, Term				5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				5,000							689,661			689,661
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 26
Deferred Credits and Other Liabilities, Noncurrent											$ 8,153,500			$ 8,153,500	6,723,500
Nonoperating Income (Expense) [Member]
Gain (Loss) on Extinguishment of Debt														$ 200,000
Pharmstandard [Member] | Subsequent Event [Member]
Percentage of Outstanding Common Stock Owned by Related Party	17.30%
Convertible Note Payable to Invetech Pty Ltd [Member]
Debt Instrument, Face Amount			$ 5,200,000
Debt Instrument, Interest Rate, Stated Percentage			6.00%
Debt Instrument, Covenant, Accrued and Unpaid Interest Reduction			$ 250,000
Debt Instrument, Convertible, Conversion Price | $ / shares			$ 10
Convertible Note Payable to Invetech Pty Ltd [Member] | Quarters Ending December 31,2017 and March 31, 2018 [Member]
Debt Instrument, Periodic Payment, Cash			$ 200,000
Convertible Note Payable to Invetech Pty Ltd [Member] | Quarters Ending December 31,2017 and March 31, 2018 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment, Shares Issue, Value			200,000
Convertible Note Payable to Invetech Pty Ltd [Member] | Quarters Ending June 30, 2018 Through March 31, 2019 [Member]
Debt Instrument, Periodic Payment, Cash			150,000
Convertible Note Payable to Invetech Pty Ltd [Member] | Quarters Ending June 30, 2018 Through March 31, 2019 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment			300,000
Debt Instrument, Periodic Payment, Shares Issue, Value			150,000
Convertible Note Payable to Invetech Pty Ltd [Member] | Quarters Ending June 30, 2019 Through June 30, 2020 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment, Cash			150,000
Convertible Promissory Note to Saint-Gobain [Member]
Debt Instrument, Face Amount		$ 2,360,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 0.50
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending December 31,2017 and March 31, 2018 [Member]
Debt Instrument, Periodic Payment, Cash		$ 200,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending December 31,2017 and March 31, 2018 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment		340,000	400,000
Debt Instrument, Periodic Payment, Shares Issue, Value		140,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending June 30, 2019 Through June 30, 2020 [Member]
Debt Instrument, Periodic Payment, Cash		100,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending June 30, 2018 Through September 30, 2018 [Member]
Debt Instrument, Periodic Payment, Cash		125,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending June 30, 2018 Through September 30, 2018 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment		245,000
Debt Instrument, Periodic Payment, Shares Issue, Value		120,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending December 31, 2018 Through March 31, 2019 [Member]
Debt Instrument, Periodic Payment, Cash		100,000
Convertible Promissory Note to Saint-Gobain [Member] | Quarters Ending December 31, 2018 Through March 31, 2019 [Member] | Maximum [Member]
Debt Instrument, Periodic Payment		220,000
Debt Instrument, Periodic Payment, Shares Issue, Value		120,000
Convertible Note Payable to Pharmstandard [Member]
Debt Instrument, Face Amount																				$ 6,000,000		$ 6,000,000
Debt Instrument, Interest Rate, Stated Percentage																					9.50%
Debt Instrument, Convertible, Conversion Price | $ / shares																					$ 10
Debt Instrument, Convertible, Conversion Prerequisite, Ownership Percentage Can Not Exceed If Converted																					39.90%
Venture Loan and Security Agreement [Member]
Debt Instrument, Face Amount					$ 25,000,000
Debt Instrument, One-Month LIBOR Basis Rate					0.50%
Debt Related Commitment Fees and Debt Issuance Costs					$ 400,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares											4,139			4,139
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares											$ 181.20			$ 181.20
Debt Instrument, Final Payment Waived in Exchange for Issuance of Warrants														$ 1,250,000
Debt Instrument, Prepayment Penalty Waived in Exchange for Issuance of Warrants														600,000
Debt Instrument, Unamortized Discount					$ 300,000
Venture Loan and Security Agreement [Member] | Prepayment on or Before Twenty Four Months of Funding Date [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance							3.00%					3.00%	3.00%
Venture Loan and Security Agreement [Member] | Prepayment After Twenty Four Months But on or Before Thirty Six Months [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance							2.00%					2.00%	2.00%
Venture Loan and Security Agreement [Member] | Prepayment After Thirty Six Months of Funding Date [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance							1.00%					1.00%	1.00%
Venture Loan and Security Agreement [Member] | LIBOR Rate In Excess of a Half a Percent [Member]
Debt Instrument, Basis Spread on Variable Rate					9.25%
Venture Loan and Security Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate					8.75%
Venture Loan and Security Agreement [Member] | Primary Tranche [Member]
Debt Instrument Tranche Amount					$ 12,500,000
Proceeds from Loans					$ 12,500,000			$ 12,500,000
Venture Loan and Security Agreement [Member] | Primary Tranche [Member] | Primary Payment Period [Member]
Debt Instrument, Term													1 year 180 days
Venture Loan and Security Agreement [Member] | Primary Tranche [Member] | Secondary Payment Period [Member]
Debt Instrument, Term													2 years
Venture Loan and Security Agreement [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage					10.75%
Venture Loan and Security Agreement [Member] | Scenario, Forecast [Member] | Primary Tranche [Member]
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid																		$ 600,000	$ 600,000
December 2013 Note [Member]
Debt Instrument, Face Amount									$ 9,000,000								$ 9,000,000
Debt Instrument, Interest Rate, Stated Percentage									3.00%								3.00%
Proceeds from Notes Payable																	$ 9,000,000
Notes Payable									$ 6,900,000		$ 5,000,000			5,000,000	6,400,000		$ 6,900,000
Debt Instrument, Interest Rate, Effective Percentage									8.00%								8.00%
Deferred Credits and Other Liabilities, Noncurrent									$ 2,100,000		$ 6,900,000			6,900,000	5,400,000		$ 2,100,000
Debt Instrument, Increase, Accrued Interest														$ 1,900,000	1,800,000
December 2013 Note [Member] | Manufacturing License [Member]
Deferred Credits and Other Liabilities, Noncurrent															2,000,000	1,000,000
November 2013 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage											8.31%			8.31%
Proceeds from Notes Payable										$ 77,832
Notes Payable											$ 13,825			$ 13,825	30,972	46,754
Debt Instrument, Number of Payments											60			60
Extinguishment of Research and Development Obligation to Invetech [Member]
Repayments of Long-term Debt			$ 500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares			57,142				57,142
Stock Issued During Period, Value, Conversion of Convertible Securities			$ 200,000
Extinguishment of Debt, Amount			8,300,000
Gain (Loss) on Extinguishment of Debt			$ 1,500,000											$ 1,500,000
Extinguishment of Research and Development Obligation to Saint-Gobain [Member]
Repayments of Long-term Debt		$ 500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares		34,499				34,499
Invetech Pty Ltd [Member]
Research and Development Obligation											$ 8,300,000			8,300,000	8,200,000
Research and Development Obligation Deferred Fees											5,200,000			5,200,000	5,200,000
Research and Development Obligation Estimated Bonus Payment											2,300,000			2,300,000	2,300,000
Research and Development Obligation Accrued Interest											700,000			700,000	600,000
Medinet [Member]
Debt Instrument, Face Amount									$ 9,000,000								$ 9,000,000
Debt Instrument, Interest Rate, Stated Percentage									3.00%								3.00%
Proceeds from Notes Payable									$ 9,000,000
Notes Payable									$ 6,900,000		$ 5,000,000			5,000,000	6,400,000		$ 6,900,000
Debt Instrument, Interest Rate, Effective Percentage									8.00%								8.00%
Reduction in Notes Payable														1,500,000	1,500,000	800,000
Reduction in Deferred Liability														500,000	500,000	$ 200,000
Deferred Revenue, Additions														2,000,000	2,000,000
Debt Instrument, Increase, Accrued Interest														$ 1,900,000	$ 1,800,000

Note 6 - Notes Payable and Co54

Note 6 - Notes Payable and Convertible Notes Payable - Notes Payable (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Long-term debt	$ 19,456,192	$ 30,148,778
Long-term portion of notes payable and convertible notes payable	12,133,543	18,673,298
Venture Loan and Security Agreement [Member]
Long-term debt, gross		24,035,029
Less debt discount and debt issuance costs		(320,409)
Long-term debt		23,714,620
Convertible Note Payable to Pharmstandard [Member]
Long-term debt	6,302,959
Convertible Note Payable to Invetech Pty Ltd [Member]
Long-term debt	5,845,655
Less current portion	(1,300,000)
Convertible Promissory Note to Saint-Gobain [Member]
Long-term debt	2,334,929
Less current portion	(1,050,000)
December 2013 Note [Member]
Long-term debt	4,958,824	6,403,186
Less current portion	(4,958,824)
July 2012 Note [Member]
Long-term debt	13,825	30,972
Other Notes Payable [Member]
Less current portion	$ (13,825)	$ (11,475,480)

Note 7 - Manufacturing Resear55

Note 7 - Manufacturing Research and Development Obligation (Details Textual) - USD ($)	Sep. 22, 2017	Mar. 06, 2017	Oct. 29, 2014	Sep. 30, 2017	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Research and Development Obligation, Current								$ 3,653,203
Extinguishment of Debt, Amount		$ 23,100,000
Gain (Loss) on Extinguishment of Debt					600,119	$ 1,506,901	2,356,478
Convertible Note Payable to Invetech Pty Ltd [Member]
Debt Instrument, Face Amount	$ 5,200,000
Extinguishment of Research and Development Obligation to Invetech [Member]
Repayments of Long-term Debt	$ 500,000
Stock Issued During Period, Shares, Conversion of Convertible Securities	57,142			57,142
Extinguishment of Debt, Amount	$ 8,300,000
Gain (Loss) on Extinguishment of Debt	$ 1,500,000						1,500,000
Invetech Pty Ltd [Member]
Research and Development Obligation					8,300,000		8,300,000	8,200,000
Research and Development Obligation Deferred Fees					5,200,000		5,200,000	5,200,000
Research and Development Obligation Estimated Bonus Payment					2,300,000		2,300,000	2,300,000
Research and Development Obligation Accrued Interest					$ 700,000		$ 700,000	600,000
Research and Development Obligation, Current								$ 3,700,000
Invetech Pty Ltd [Member]
Deferred Research and Development Manufacturing Service Costs Percentage			30.00%
Maximum Deferred Research and Development Manufacturing Service Costs			$ 5,000,000

Note 8 - Facility Lease Oblig56

Note 8 - Facility Lease Obligation, Capital Lease Obligations, Assets Held for Sale and Sold (Details Textual)	1 Months Ended			3 Months Ended																12 Months Ended
	Aug. 31, 2016USD ($)	Feb. 28, 2015USD ($)	Aug. 31, 2014USD ($)ft²	Dec. 31, 2017USD ($)		Sep. 30, 2017USD ($)		Jun. 30, 2017USD ($)		Mar. 31, 2017USD ($)		Dec. 31, 2016USD ($)		Sep. 30, 2016USD ($)	[2]	Jun. 30, 2016USD ($)	[2]	Mar. 31, 2016USD ($)	[2]	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Payments to Acquire Property, Plant, and Equipment																				$ 3,674,358	$ 15,329,980	$ 9,686,643
Assets Held-for-sale, Not Part of Disposal Group, Current				$ 600,000								$ 1,452,172								600,000	1,452,172
Impairment of Long-Lived Assets to be Disposed of				50,036	[1]		[1]		[1]	$ 27,204,349	[1]	741,114	[2]							27,254,385	741,114
Proceeds from Sale of Property, Plant, and Equipment																				3,250,631
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property				2,767,540	[3]		[3]		[3]		[3]									2,767,540
Property, Plant and Equipment, Gross				13,261,888								49,845,761								13,261,888	49,845,761
Various Equipment [Member]
Assets Held-for-sale, Not Part of Disposal Group, Current				700,000																700,000
Impairment of Long-Lived Assets to be Disposed of																				1,100,000
Construction in Progress [Member]
Impairment of Long-Lived Assets to be Disposed of																				6,100,000
Property, Plant and Equipment, Gross												28,807,957									28,807,957
Centerpoint Facility [Member]
Proceeds from Sale of Property, Plant, and Equipment																				1,800,000
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property																				1,800,000
Lease Agreement [Member]
Facility Lease Obligation Building Area | ft²			125,000
Payments to Acquire Property, Plant, and Equipment		$ 1,700,000	$ 1,700,000
Lessee Leasing Arrangements, Term of Contract			10 years
Lessee Leasing Arrangements, Number of Renewal Terms			6
Capital Lease, Future Monthly Payments				49,052																49,052
Security Deposit			$ 1,300,000
Capital Leases, Balance Sheet, Assets by Major Class, Net		$ 7,400,000										7,900,000									7,900,000
Assets Held-for-sale, Not Part of Disposal Group												7,400,000									7,400,000
Lessee Leasing Arrangements, Renewal Term			5 years
Lease Agreement [Member] | Restricted Cash [Member]
Security Deposit				700,000																700,000		$ 700,000
Centerpoint Facility [Member] | Construction in Progress [Member]
Impairment of Long-Lived Assets to be Disposed of																				18,300,000
Power Generation Agreements [Member]
Lessee Leasing Arrangements, Term of Contract	10 years 240 days
Capital Leases, Number of Contracts	2
Capital Leases, Monthly Payments	$ 32,948
Capital Leases, Future Minimum Payments Due	$ 4,200,000
Power Generation Agreements [Member] | Construction in Progress [Member]
Impairment of Long-Lived Assets to be Disposed of																				100,000
Property, Plant and Equipment, Gross				$ 0								$ 2,400,000								$ 0	$ 2,400,000
[1]	Represents impairment loss on property and equipment held for sale in the three months ended March 31, 2017 and three months ended December 31, 2017; none present in other periods presented.
[2]	Represents impairment loss on property and equipment held for sale in the three months ended December 31, 2016; none present in other periods presented.
[3]	Represents a gain on sale of impaired property in the three months ended December 31, 2017 from the disposal of the Centerpoint property and certain other property in the Saint-Gobain debt restructuring.

Note 9 - Common Stock (Details

Note 9 - Common Stock (Details Textual) - USD ($)	Nov. 22, 2017	Sep. 22, 2017	Mar. 06, 2017	Aug. 02, 2016	Jun. 29, 2016	Mar. 14, 2016	Mar. 04, 2016	Jan. 08, 2016	May 08, 2015	Apr. 07, 2015	Feb. 28, 2018	Nov. 30, 2017	Sep. 30, 2017	Jun. 30, 2017	Jan. 31, 2017	Aug. 31, 2016	Mar. 09, 2018	Dec. 31, 2017		Sep. 30, 2017	[1]	Jun. 30, 2017	[1]	Mar. 31, 2017	[1]	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 16, 2018	Apr. 17, 2017	Nov. 20, 2016
Stock Issued During Period, Shares, New Issues										50,000
Proceeds from Issuance of Common Stock										$ 10,110,000
Restricted Stock Awards Granted in Lieu of Annual Cash Bonuses, Shares, Percentage of Annual Cash Bonus Used in Calculation															25.00%
Stock Issued During Period, Shares, Restricted Stock Award, Gross								296,936							4,005
Stock Issued During Period, Value, Restricted Stock Award, Gross								$ 665,137							$ 400,000
Restricted Stock Awards, Lapsing Right of Repurchase, Percentage of Underlying Shares																															100.00%	100.00%
Allocated Share-based Compensation Expense																											$ 8,867,616	$ 5,394,492	$ 4,014,938
Restructuring Charges																			[1]	$ 679,013		$ 344,474		$ 5,008,292			$ 6,031,779
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number																		91,923									91,923
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options																		$ 14,848									$ 14,848
Stock Issued During Period, Value, New Issues																											$ 15,464,383		$ 10,681,432
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			5,000															689,661									689,661
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 26
Class of Warrant or Right, Term			5 years
Share Price	$ 4.06									$ 171.40								$ 3									$ 3
Stock Issued During Period, Value, Issued for Services																												289,001
Shares Issued, Price Per Share										$ 202.20
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										18.00%
Purchase Agreement Aggregate Investment										$ 20,000,000
Royalty Arrangement [Member]
Proceeds from Issuance of Common Stock										1,540,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues																											3,373,967		95,309
Stock Issued During Period, Shares, Conversion of Convertible Securities																											91,643
Stock Issued During Period, Value, New Issues																											$ 3,374		$ 95
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 26
Share Price								$ 2.24
Stock Issued During Period, Value, Issued for Services																												$ 3
Stock Issued During Period, Shares, Issued for Services																												2,608
Additional Paid-in Capital [Member]
Proceeds from Issuance of Common Stock										8,570,000
Stock Issued During Period, Value, New Issues																											15,461,009		10,681,337
Stock Issued During Period, Value, Issued for Services																												$ 288,998
Extinguishment of Research and Development Obligation to Invetech [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities		57,142											57,142
Extinguishment of Research and Development Obligation to Saint-Gobain [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities	34,499											34,499
Research and Development Expense [Member]
Allocated Share-based Compensation Expense																											2,424,924	2,818,618	2,104,401
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense																											$ 3,226,844	$ 2,575,874	1,910,537
43 Employees [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross																											369,998
Stock Issued During Period, Value, Restricted Stock Award, Gross																											$ 1,400,000
Employee [Member]
Stock Issued During Period, Shares, Share-based Compensation, Gross														2,333
Employee [Member] | General and Administrative Expense [Member]
Allocated Share-based Compensation Expense																											$ 20,999
Nonemployee Directors [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues																												52,173
Stock Issued During Period, Value, Issued for Services																												$ 288,999
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period																											368	1,350
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period																											28,689	14,514
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number																												6,919
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																												22,783
Restricted Stock [Member] | 43 Employees [Member] | Research and Development Expense [Member]
Allocated Share-based Compensation Expense																											$ 800,000
Restricted Stock [Member] | 43 Employees [Member] | General and Administrative Expense [Member]
Allocated Share-based Compensation Expense																											500,000
Restricted Stock [Member] | Employees [Member]
Allocated Share-based Compensation Expense																												$ 169,504
Restricted Stock [Member] | Employees [Member] | Research and Development Expense [Member]
Allocated Share-based Compensation Expense																												37,115
Restricted Stock [Member] | Employees [Member] | General and Administrative Expense [Member]
Allocated Share-based Compensation Expense																												$ 134,388
Awards Vested Upon Termination [Member]
Restructuring Charges																											$ 100,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period																												12,744
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number																												9,104
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																												21,848
Restricted Stock Units (RSUs) [Member] | Employees [Member]
Allocated Share-based Compensation Expense																												$ 1,999
Employee and Consultant [Member] | Restricted Stock and RSU [Member]
Allocated Share-based Compensation Expense																												$ 171,503
Sales Agreement, At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues																											3,373,967	43,634
Proceeds from Issuance of Common Stock																										$ 6,000,000	$ 15,500,000	$ 5,500,000
Underwritten Offering [Member]
Stock Issued During Period, Shares, New Issues				454,545												454,545
Proceeds from Issuance or Sale of Equity				$ 48,200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				340,909												340,909
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right				0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 110												$ 110
Share Price				$ 110
Additional Shares the Purchasers Have Agreed to Purchase [Member]
Stock Issued During Period, Value, New Issues										$ 10,000,000
Subsequent Event [Member] | Sales Agreement, At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues																	3,982,865
Proceeds from Issuance of Common Stock																	$ 7,300,000
Common Stock Sales Agreement, Remaining Amount																														$ 15,800,000
Cowen and Company LLC [Member] | Maximum [Member]
Common Stock Sales Agreement, Amount									$ 30,000,000
Common Stock Sales Agreement, Commission of Gross Proceeds									3.00%
Cowen and Company LLC [Member] | Maximum [Member] | Subsequent Event [Member]
Common Stock Sales Agreement, Amount											$ 45,000,000
Investors [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues					273,933	182,621
Proceeds from Issuance or Sale of Equity							$ 60,000,000
Stock Issued During Period, Value, New Issues					$ 29,800,000	$ 19,900,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					205,450	136,966
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						0.75
Sale of Stock, Price Per Share						$ 108.875
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 107	$ 107
Class of Warrant or Right, Term					5 years
Cellscript, LLC [Member] | Master Process Development and Supply Agreement [Member]
Stock Issued During Period, Value, Issued for Services																													2,111,432
Development and Production Services Fees																													$ 4,600,000
Stock Issued During Period, Shares, Issued for Services																													45,309
Shares of Common Stock Issued Pursuant to the Specified Agreement, Lock-up Period																													180 days
[1]	Represents costs of a reduction-in-force and early termination of a lease agreement implemented in March 2017.

Note 10 - Warrants (Details Tex

Note 10 - Warrants (Details Textual) - USD ($)	Mar. 06, 2017	Aug. 02, 2016	Jun. 29, 2016	Mar. 14, 2016	Apr. 07, 2015	Aug. 31, 2016	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Nov. 30, 2013
Stock Issued During Period, Value, New Issues								$ 15,464,383		$ 10,681,432
Stock Issued During Period, Shares, New Issues					50,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000							689,661
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 26
Proceeds from Warrant Exercises									$ 299,932
Class of Warrant or Right, Term	5 years
Fair Value Assumptions, Expected Dividend Rate								0.00%
August 2016, Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		340,909
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 110
Warrants and Rights Outstanding								$ 167,636	$ 20,926,061
Fair Value Assumptions, Expected Dividend Rate						0.00%		0.00%	0.00%
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, New Issues								$ 15,461,009		$ 10,681,337
Lenders and Affiliates [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 26
Class of Warrant or Right, Term	5 years
Lenders and Affiliates [Member] | Additional Paid-in Capital [Member]
Warrants and Rights Outstanding								$ 87,100
Pharmstandard [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											24,989
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 116.40
Private Placement [Member] | Investors [Member]
Stock Issued During Period, Value, New Issues			$ 29,800,000	$ 19,900,000
Stock Issued During Period, Shares, New Issues			273,933	182,621
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			205,450	136,966
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 107	$ 107
Class of Warrant or Right, Exercised During Period							2,803
Proceeds from Warrant Exercises							$ 300,000
Class of Warrant or Right, Term			5 years
Underwritten Offering [Member]
Stock Issued During Period, Shares, New Issues		454,545				454,545
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		340,909				340,909
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 110				$ 110
Total Purchase Price of Shares and Warrants Sold						$ 50,000,000

Note 10 - Warrants - Outstandin

Note 10 - Warrants - Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Mar. 06, 2017
Number of shares (in shares)	689,661	5,000
Exercise price (in dollars per share)		$ 26
Warrant One [Member]
Number of shares (in shares)	4,139
Exercise price (in dollars per share)	$ 181.20
Expiration date	Sep. 29, 2021
Warrant Two [Member]
Number of shares (in shares)	134,163
Exercise price (in dollars per share)	$ 107
Expiration date	Mar. 4, 2021
Warrant Three [Member]
Number of shares (in shares)	205,450
Exercise price (in dollars per share)	$ 107
Expiration date	Jun. 29, 2021
Warrant Four [Member]
Number of shares (in shares)	340,909
Exercise price (in dollars per share)	$ 110
Expiration date	Aug. 2, 2021
Warrant Five [Member]
Number of shares (in shares)	5,000
Exercise price (in dollars per share)	$ 26
Expiration date	Mar. 6, 2022

Note 10 - Warrants - August 201

Note 10 - Warrants - August 2016, Warrants (Details) - $ / shares	Aug. 02, 2016	Dec. 31, 2017	Mar. 06, 2017
Exercise price (in dollars per share)			$ 26
Number of Shares Called by Warrants (in shares)		689,661	5,000
August 2016, Warrant [Member]
Exercise price (in dollars per share)	$ 110
Expiration date	Aug. 2, 2021
Number of Shares Called by Warrants (in shares)	340,909

Note 10 - Warrants - Warrants V

Note 10 - Warrants - Warrants Valuation Assumptions (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Aug. 31, 2016	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Nov. 22, 2017	Apr. 07, 2015
Closing underlying stock price on date of valuation (in dollars per share)			$ 3			$ 4.06	$ 171.40
Fair Value Assumptions, Expected Dividend Rate			0.00%
Decrease in fair value of warrant liability		$ 20,357,323	$ (20,758,425)	$ (1,007,352)
August 2016, Warrant [Member]
Exercise price of warrants (in dollars per share)			$ 110	$ 110
Closing underlying stock price on date of valuation (in dollars per share)			$ 3	$ 98
Expected stock price volatility			112.00%	84.00%
Expected life (in years) (Year)			3 years 211 days	4 years 211 days
Risk-free interest rate			2.04%	1.93%
Fair Value Assumptions, Expected Dividend Rate	0.00%		0.00%	0.00%
Valuation per common share underlying each warrant (in dollars per share)			$ 0.49	$ 61.38
Total liability for warrants on the consolidated balance sheet			$ 167,636	$ 20,926,061
Decrease in fair value of warrant liability			$ 20,758,425	$ 1,007,352

Note 11 - Stock Options and E62

Note 11 - Stock Options and Employee Stock Purchase Plan (Details Textual) - USD ($)	Jul. 28, 2017	Apr. 07, 2015	Jul. 28, 2014	Jan. 31, 2014	Aug. 31, 2017	Feb. 28, 2017	Aug. 31, 2016	Feb. 29, 2016	Aug. 31, 2015	Feb. 27, 2015	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Nov. 22, 2017	Mar. 01, 2016	Sep. 01, 2015	Mar. 02, 2015	Sep. 02, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		18.00%
Share Price		$ 171.40													$ 3			$ 4.06
Allocated Share-based Compensation Expense															$ 8,867,616	$ 5,394,492	$ 4,014,938
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense															$ 0
Fair Value Assumptions, Expected Dividend Rate															0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value															$ 72.91	$ 76.80	$ 115.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value															$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															70,604
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price															$ 95.38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value															$ 7,400,000	$ 4,400,000	$ 3,400,000
Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized															$ 6,000,000
Employee Stock Option [Member] | Scenario, Forecast [Member]
Allocated Share-based Compensation Expense											$ 50,000	$ 1,300,000	$ 2,000,000	$ 2,600,000
Employees and Non-employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			6,495
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 121.80
The 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				570,746
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Future Increases in the Number of Shares Authorized	250,000			250,000
Share-based Compensation Arrangement by Share-based Payment Award, Future Increases in the Number of Shares Authorized, Percent of Shares Outstanding	4.00%			4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Automatic Annual Increase	134,548
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Before Annual Increases	570,746
Common Stock, Capital Shares Reserved for Future Issuance															252,898
The 2014 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate				10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent				85.00%
Employee Stock Purchase Plan (ESPP), Number of Shares Allocated					999	428	1,507	1,814	1,015	652
Share Price					$ 4	$ 23	$ 99	$ 88.80	$ 124.20	$ 180.40									$ 98.20	$ 124.80	$ 180.40	$ 196.60
Allocated Share-based Compensation Expense					$ 17,711	$ 30,064	$ 63,788	$ 107,455	$ 72,800	$ 54,508
Common Stock, Capital Shares Reserved for Future Issuance															10,899

Note 11 - Stock Options and E63

Note 11 - Stock Options and Employee Stock Purchase Plan - Stock-based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stock-based compensation expense	$ 8,867,616	$ 5,394,492	$ 4,014,938
Research and Development Expense [Member]
Stock-based compensation expense	2,424,924	2,818,618	2,104,401
General and Administrative Expense [Member]
Stock-based compensation expense	3,226,844	2,575,874	1,910,537
Restructuring Charges [Member]
Stock-based compensation expense	$ 3,215,848

Note 11 - Stock Options and E64

Note 11 - Stock Options and Employee Stock Purchase Plan - Stock Option Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Stock Option Plans [Member]
Risk-free interest rate	2.26%	1.50%	2.05%
Expected dividend yield	0.00%	0.00%	0.00%
Expected stock option term (in years) (Year)	7 years	7 years	7 years
Expected volatility	86.00%	82.00%	87.00%
Employee Stock Purchase Plan [Member]
Expected dividend yield	0.00%	0.00%	0.00%
Expected stock option term (in years) (Year)	182 days	182 days	182 days
Employee Stock Purchase Plan [Member] | Minimum [Member]
Risk-free interest rate	0.69%	0.47%	0.07%
Expected volatility	141.00%	113.00%	45.00%
Employee Stock Purchase Plan [Member] | Maximum [Member]
Risk-free interest rate	0.79%	0.50%	0.26%
Expected volatility	210.00%	141.00%	58.00%

Note 11 - Stock Options and E65

Note 11 - Stock Options and Employee Stock Purchase Plan - Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Number of Shares Outstanding (in shares) | shares	245,141
Weighted Average Exercise Price, Outstanding (in dollars per share) | $ / shares	$ 121.40
Number of Shares Granted (in shares) | shares	70,604
Weighted Average Exercise Price, Granted (in dollars per share) | $ / shares	$ 95.38
Number of Shares Exercised (in shares) | shares
Weighted Average Exercise Price, Exercised (in dollars per share) | $ / shares
Number of Shares Cancelled (in shares) | shares	(46,231)
Weighted Average Exercise Price, Cancelled (in dollars per share) | $ / shares	$ 97.58
Number of Shares Outstanding (in shares) | shares	269,514
Weighted Average Exercise Price, Outstanding (in dollars per share) | $ / shares	$ 111.91
Weighted Average Contractual Term, Outstanding (Year)	5 years 211 days
Number of Shares Exercisable (in shares) | shares	182,039
Weighted Average Exercise Price, Exercisable (in dollars per share) | $ / shares	$ 117.01
Weighted Average Contractual Term, Exercisable (Year)	4 years 51 days
Number of Shares Vested and Expected to Vest (in shares) | shares	262,778
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share) | $ / shares	$ 112.19
Weighted Average Contractual Term, Vested and Expected to Vest (Year)	5 years 240 days

Note 11 - Stock Options and E66

Note 11 - Stock Options and Employee Stock Purchase Plan - Summary of Stock Options (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Options Outstanding (in shares)	269,514
Weighted Average Contractual Life (Year)	5 years 211 days
Options Exercisable (in shares)	176,414
Exercise Price Range 1 [Member]
Exercise Price or Range of Exercise Price, Lower (in dollars per share) | $ / shares	$ 3.40
Exercise Price or Range of Exercise Price, Upper (in dollars per share) | $ / shares	$ 3.40
Options Outstanding (in shares)	1,500
Weighted Average Contractual Life (Year)	9 years 270 days
Options Exercisable (in shares)	125
Exercise Price Range 2 [Member]
Exercise Price or Range of Exercise Price, Lower (in dollars per share) | $ / shares	$ 27
Exercise Price or Range of Exercise Price, Upper (in dollars per share) | $ / shares	$ 99
Options Outstanding (in shares)	87,411
Weighted Average Contractual Life (Year)	5 years 270 days
Options Exercisable (in shares)	44,601
Exercise Price Range 3 [Member]
Exercise Price or Range of Exercise Price, Lower (in dollars per share) | $ / shares	$ 101
Exercise Price or Range of Exercise Price, Upper (in dollars per share) | $ / shares	$ 185.60
Options Outstanding (in shares)	179,740
Weighted Average Contractual Life (Year)	5 years 292 days
Options Exercisable (in shares)	130,825
Exercise Price Range 4 [Member]
Exercise Price or Range of Exercise Price, Lower (in dollars per share) | $ / shares	$ 217.22
Exercise Price or Range of Exercise Price, Upper (in dollars per share) | $ / shares	$ 221.80
Options Outstanding (in shares)	800
Weighted Average Contractual Life (Year)	6 years 317 days
Options Exercisable (in shares)	800
Exercise Price Range 5 [Member]
Exercise Price or Range of Exercise Price, Lower (in dollars per share) | $ / shares	$ 705.97
Exercise Price or Range of Exercise Price, Upper (in dollars per share) | $ / shares	$ 733.20
Options Outstanding (in shares)	63
Weighted Average Contractual Life (Year)	3 years 251 days
Options Exercisable (in shares)	63

Note 12 - Collaboration Agree67

Note 12 - Collaboration Agreements (Details Textual) - USD ($)	Feb. 01, 2018	Apr. 07, 2015	Jul. 31, 2013	Mar. 31, 2018	Oct. 31, 2017	Jun. 30, 2016	Jul. 31, 2015	Dec. 31, 2013	Apr. 02, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Feb. 14, 2018	Mar. 06, 2017	Nov. 30, 2013	Aug. 31, 2013
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										689,661				5,000
Class of Warrant or Right, Exercise Price of Warrants or Rights														$ 26
Stock Issued During Period, Shares, New Issues		50,000
Deferred Credits and Other Liabilities, Noncurrent										$ 8,153,500	$ 6,723,500
Pharmstandard and Actigen Option Agreement [Member] | Subsequent Event [Member]
Collaborative Arrangement, Upfront License Fee	$ 3,600,000
Collaborative Arrangement, Development and Regulatory Milestone Payments	$ 8,500,000
Collaborative Arrangement, Royalty Payment, Minimum Term	10 years
Collaborative Arrangement, Development Expenditures Credited as Prepaid Royalties	$ 5,000,000
Medinet [Member]
Debt Instrument, Face Amount								$ 9,000,000
Lummy License Agreement [Member]
Revenue Recognition Milestone Method, Maximum Revenue										$ 22,300,000
License Agreement Royalty Term										10 years
Proceeds from Milestone Payments					$ 1,500,000
Revenue Recognition, Milestone Method, Revenue Recognized					$ 1,500,000
Lummy License Agreement [Member] | Subsequent Event [Member]
Proceeds from Milestone Payments				$ 1,050,000
Pharmstandard [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights															24,989
Class of Warrant or Right, Exercise Price of Warrants or Rights															$ 116.40
Pharmstandard [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues									169,014
Green Cross [Member]
Royalty Contract Term			15 years
Green Cross [Member] | Initial Submission of Application for Regulatory Approval [Member]
Royalty Guarantees, Commitments, Amount			$ 500,000
Medinet [Member]
Royalty Guarantees, Commitments, Amount								5,000,000
Debt Instrument, Face Amount								9,000,000
Proceeds from License Fees Received						$ 2,000,000	$ 1,000,000	1,000,000		$ 2,000,000
Proceeds from Notes Payable								$ 9,000,000
Debt Instrument, Principal Balance										4,000,000
Debt Instrument, Interest Rate, Stated Percentage								3.00%
Notes Payable								$ 6,900,000		5,000,000	6,400,000
Debt Instrument, Interest Rate, Effective Percentage								8.00%
Deferred Revenue												$ 1,000,000
Reduction in Notes Payable										1,500,000	1,500,000	800,000
Reduction in Deferred Liability										500,000	500,000	$ 200,000
Deferred Revenue, Additions										2,000,000	2,000,000
Debt Instrument, Increase, Accrued Interest										1,900,000	1,800,000
Medinet [Member] | Nonsoftware License Arrangement [Member]
Deferred Credits and Other Liabilities, Noncurrent								$ 1,000,000
Medinet [Member] | Below Market Rate Adjustment [Member]
Deferred Credits and Other Liabilities, Noncurrent								2,100,000		$ 6,900,000	$ 5,400,000
Medinet [Member] | Subsequent Event [Member]
Deferred Revenue													$ 5,800,000
Maximum [Member]
Royalties Percent of Net Sales										4.00%
Maximum [Member] | Pharmstandard [Member]
Royalties Percent of Net Sales																20.00%
Maximum [Member] | Green Cross [Member]
Royalties Percent of Net Sales			20.00%
Maximum [Member] | Medinet [Member] | Developmental and Regulatory Milestones [Member]
Royalty Guarantees, Commitments, Amount								$ 9,000,000

Note 13 - Commitments (Details

Note 13 - Commitments (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Leases, Rent Expense, Net	$ 1,296,280	$ 1,098,452	$ 536,932
Minimum [Member]
Royalties Percent of Net Sales	1.00%
Maximum [Member]
Royalties Percent of Net Sales	4.00%

Note 13 - Commitments - Future

Note 13 - Commitments - Future Minimum Lease Payments (Details)	Dec. 31, 2017USD ($)
2,018	$ 602,177
2,019	640,309
2,020	656,272
2,021	650,607
2,022	376,205
Thereafter	29,699
Total minimum lease payments	$ 2,955,269

Note 14 - Employee Benefit Pl70

Note 14 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	25.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	6.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 243,598	$ 350,646	$ 334,487

Note 15 - Net Loss Per Share -

Note 15 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net loss attributable to common stockholders	$ (1,892,871)	$ (6,065,947)	$ (8,538,611)	$ (24,080,081)	$ (15,354,836)	$ (12,246,841)	$ (12,606,245)	$ (12,820,188)	$ (40,577,510)	$ (53,028,110)	$ (74,788,521)
Weighted average shares outstanding, basic and diluted (in shares)	4,992,418	2,911,800	2,068,743	2,065,676	2,062,257	1,896,911	1,303,308	1,130,331	3,017,409	1,600,286	1,022,862
Net loss attributable to common stockholders per share, basic and diluted (in dollars per share)	$ (0.38)	$ (2.08)	$ (4.13)	$ (11.66)	$ (7.45)	$ (6.46)	$ (9.67)	$ (11.34)	$ (13.45)	$ (33.14)	$ (73.12)

Note 15 - Net Loss Per Share 72

Note 15 - Net Loss Per Share - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Employee Stock Option [Member]
Antidilutive Securities (in shares)	283,443	211,509	157,451
Warrant [Member]
Antidilutive Securities (in shares)	688,771	356,339	4,139
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	518,382

Note 16 - Selected Quarterly 73

Note 16 - Selected Quarterly Data (Unaudited) (Details Textual) - USD ($)	3 Months Ended			12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value Adjustment of Warrants			$ 20,357,323	$ (20,758,425)	$ (1,007,352)
Gain (Loss) on Extinguishment of Debt	$ 600,119	$ 1,506,901		$ 2,356,478

Note 16 - Selected Quarterly 74

Note 16 - Selected Quarterly Data (Unaudited) - Quarterly Data (Details) - USD ($)	3 Months Ended																12 Months Ended
	Dec. 31, 2017		Sep. 30, 2017		Jun. 30, 2017		Mar. 31, 2017		Dec. 31, 2016		Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues	$ 1,670,949		$ 53,497		$ 69,693		$ 105,259		$ 163,640		$ 146,756		$ 488,643		$ 146,429		$ 1,899,398	$ 945,468	$ 518,329
Research and development	4,070,962		4,550,353		5,120,952		7,913,829		10,301,058		9,340,018		9,164,184		9,501,976		21,656,096	38,307,236	62,054,823
General and administrative	2,661,466		2,879,011		2,679,867		3,962,891		4,828,280		3,010,518		3,389,479		2,975,024		12,183,235	14,203,301	11,011,011
Impairment of Long-Lived Assets to be Disposed of	50,036	[1]		[1]		[1]	27,204,349	[1]	741,114	[2]		[2]		[2]		[2]	27,254,385	741,114
Operating loss	(2,343,975)	[3]	(8,054,880)	[3]	(8,075,600)	[3]	(43,984,102)	[3]	(15,706,812)		(12,203,780)		(12,065,020)		(12,330,571)		(62,458,557)	(52,306,183)	(72,547,505)
Other income (expense)	451,104	[3]	1,988,933	[3]	(463,011)	[3]	19,904,021	[3]	351,976		(43,061)		(541,225)		(489,617)		9,860	(11,865)	(2,799)
Net loss	$ (1,892,871)		$ (6,065,947)		$ (8,538,611)		$ (24,080,081)		$ (15,354,836)		$ (12,246,841)		$ (12,606,245)		$ (12,820,188)		$ (40,577,510)	$ (53,028,110)	$ (74,788,521)
Net loss attributable to common stockholders per share, basic and diluted (in dollars per share)	$ (0.38)		$ (2.08)		$ (4.13)		$ (11.66)		$ (7.45)		$ (6.46)		$ (9.67)		$ (11.34)		$ (13.45)	$ (33.14)	$ (73.12)
Weighted average shares outstanding, basic and diluted (in shares)	4,992,418		2,911,800		2,068,743		2,065,676		2,062,257		1,896,911		1,303,308		1,130,331		3,017,409	1,600,286	1,022,862
Restructuring Charges		[4]	$ 679,013	[4]	$ 344,474	[4]	$ 5,008,292	[4]									$ 6,031,779
Gain on disposal of impaired property (3)	$ (2,767,540)	[5]		[5]		[5]		[5]									$ (2,767,540)
[1]	Represents impairment loss on property and equipment held for sale in the three months ended March 31, 2017 and three months ended December 31, 2017; none present in other periods presented.
[2]	Represents impairment loss on property and equipment held for sale in the three months ended December 31, 2016; none present in other periods presented.
[3]	Primarily represents gain on change in value of warrants classified as liabilities of $20,357,323 in the three months ended March 31, 2017 and a gain on early extinguishment of debt of $1,506,901 and $600,119 in the three months ended September 30, 2017 and December 31, 2017, respectively.
[4]	Represents costs of a reduction-in-force and early termination of a lease agreement implemented in March 2017.
[5]	Represents a gain on sale of impaired property in the three months ended December 31, 2017 from the disposal of the Centerpoint property and certain other property in the Saint-Gobain debt restructuring.

Note 18 - Subsequent Events (De

Note 18 - Subsequent Events (Details Textual) - USD ($)	Apr. 07, 2015	Mar. 31, 2018	Oct. 31, 2017	Dec. 31, 2017	Dec. 31, 2015	Feb. 14, 2018	Jan. 06, 2018
Stock Issued During Period, Shares, New Issues	50,000
Stock Issued During Period, Value, New Issues				$ 15,464,383	$ 10,681,432
Medinet [Member]
Deferred Revenue					$ 1,000,000
Lummy License Agreement [Member]
Proceeds from Milestone Payments			$ 1,500,000
Subsequent Event [Member] | Medinet [Member]
Deferred Revenue						$ 5,800,000
Subsequent Event [Member] | Lummy License Agreement [Member]
Proceeds from Milestone Payments		$ 1,050,000
Subsequent Event [Member] | Stock Purchase Agreement with Lummy [Member]
Stock Issued During Period, Shares, New Issues		375,000
Stock Purchase Agreement, Aggregate Purchase Price							$ 1,500,000
Stock Issued During Period, Value, New Issues		$ 450,000

Schedule II - Valuation and Q76

Schedule II - Valuation and Qualifying Accounts - Deferred Tax Asset Valuation Allowance (Details) - Valuation Allowance of Deferred Tax Assets [Member] - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Balance at beginning of year		$ 102,594	$ 84,903	$ 68,197
Additions charged to expenses	[1]	(18,700)	17,691	16,706
Balance at end of year		$ 83,894	$ 102,594	$ 84,903
[1]	Impact of providing full valuation allowance against all deferred tax assets since the Company could not assert that it was more likely than not that these deferred tax assets would be realized.